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Abstract: A novel rat model for a well-characterized human mitochondrial 
disease, mitochondrial DNA depletion syndrome with associated 
deoxyguanosine kinase (DGUOK) deficiency, is described. The rat model 
recapitulates the pathologic and biochemical signatures of the human disease. 
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The application of electron paramagnetic (spin) resonance (EPR) spectroscopy 
to the identification and characterization of respiratory chain abnormalities in 
the mitochondria from freshly frozen tissue of the mitochondrial disease 
model rat is introduced. EPR is shown to be a sensitive technique for 
detecting mitochondrial functional abnormality in situ and, here, is particularly 
useful in characterizing the redox state changes and oxidative stress that can 
result from depressed expression and/or diminished specific activity of the 
distinct respiratory chain complexes. As EPR requires no sample preparation 
or non-physiological reagents, it provides information on the status of the 
mitochondrion as it was in the functioning state. On its own, this information 
is of use in identifying respiratory chain dysfunction; in conjunction with other 
techniques, the information from EPR shows how the respiratory chain is 
affected at the molecular level by the dysfunction. It is proposed that EPR has 
a role in mechanistic pathophysiological studies of mitochondrial disease and 
strong potential as an additional diagnostic tool. 
Keywords: DGUOK, redox, oxidative, stress, mtDNA depletion, pathology 
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Mitochondrial disease (MD) occurs where depletion of 
mitochondrial DNA (mtDNA) or mutations in mtDNA and/or nuclear 
DNA (nDNA) lead to altered mitochondrial function.1–4 Altered activities 
of Complexes I – V have been identified and physiological 
consequences of mitochondrial respiratory chain defects include 
reduced metabolic capacity, reduced ATP synthesis, and increased 
oxidative and nitrosative stress.5–15 Symptoms of MD are manifold and 
include weakness (from central nervous system, peripheral nerve, 
and/or skeletal muscle disease), pain, intolerance of some general 
anesthetics and anti-epileptic drugs, gastrointestinal disorders, 
ophthalmoplegia and/or visual failure, failure to thrive, cardiac and 
respiratory disease, liver disease, diabetes, seizures, sensorineural 
hearing loss, mental retardation, dementia, movement disorders, 
increased susceptibility to infection, and pregnancy loss.1,2,16–38 
Establishing diagnoses and understanding the pathophysiology of 
mitochondrial disease (MD) has proven extremely challenging because 
of the extraordinary range of clinical symptoms and testing 
abnormalities.39 MD is often suspected in early childhood from clinical 
differential diagnosis of patients with diseases involving the brain, 
muscle, or liver. Traditional methods for diagnosing MD include clinical 
presentation, family history, pathology, metabolic profiling, enzyme 
activity levels, electrophysiology, magnetic resonance imaging (MRI) 
of brain and magnetic resonance spectroscopy (MRS) of metabolites, 
and mtDNA analysis.3,7,31,40–53 Additional indicators include observation 
of mitochondrial proliferation, abnormalities on muscle histology (e.g., 
ragged red fibers or succinate dehydrogenase-positive fibers),41,54 and 
abnormalities in electron microscopy.46,55 However, muscle histology 
may be normal despite the presence of biochemical abnormalities in 
the tissue. The determination of whether MD is present in a given 
patient can be extremely complex, given that (i) mitochondrial 
function can be secondarily affected due to the disease processes in 
non-mitochondrial diseases, (ii) there can be extensive variability in 
the distribution of abnormal mitochondria within an individual patient, 
allowing a “false negative” testing profile to occur when tissues with 
mitochondrial abnormalities are not tested, and (iii) there are no 
uniform, definitive pathological abnormalities that distinguish all MD 
patients from patients with other disorders. Diagnosis may ultimately 
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rely on the application of diagnostic algorithms to predict the likelihood 
of MD56,57 but MD is currently an under-diagnosed disease.4,58–64 
Mechanistic information on MD has largely arisen from 
mitochondrial electron transport chain component activity assays on 
the components, isolated from their native matrix from fresh or frozen 
tissue, or from cultured cells. These assays are, like most clinical 
biochemical assays, performed under non-physiologic basal conditions 
and with very different substrate concentrations than are seen in-vivo. 
Complex interactions between the substrates of these assays and 
other cellular components can lead to erroneous results65 though these 
problems can, in principle be, overcome with careful isolation of 
proteins or in-gel assays. Assays of activities outside of the intact 
mitochondrial environment cannot identify defects in mitochondrial 
membrane potential or coupling. In clinical practice, it has been found 
that the methodological variations, limitations and difficulties 
associated with the use of respiratory chain functional assays as a 
diagnostic method for MD has led to massive inter-laboratory 
variability in results.66 In alternative approaches, substrates are added 
to whole cells or isolated mitochondrial preparations, and either 
oxygen consumption or ATP generation is measured [reviewed in]67 
While recognized as the current standard for mitochondrial testing 
there are, again, significant limitations. Most apparent is the 
requirement for viable functioning mitochondria, requiring cell 
preparation or mitochondrial isolation and testing to be carried out 
temporally, and therefore geographically, proximate to the biopsy. The 
process of isolating mitochondria from native tissue risks damage and 
places the organelle outside of a truly physiologic condition. 
Conversely, whole cell assays require permeabilization of the cell to 
the substrates and transport to the mitochondria. The potentially 
limited ability to get reagents to the site of action can lead to a loss of 
sensitivity and specificity. In all of the currently employed assays, the 
mitochondrial function is not assessed in its native-organ context in 
the human and the need persists for an assay that measures the 
functional ability of mitochondria in an intact tissue preserved in a 
state as close as possible to that in situ. 
Electron paramagnetic (spin) resonance (EPR, ESR) is a 
technique that can provide unique insight into mitochondrial status. 
EPR detects and characterizes free radicals and many transition metal 
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ions and clusters in biological systems by measuring the magnetic field 
dependence of the absorption of microwave radiation at a given 
frequency by the unpaired electrons residing in these species.68 The 
mitochondrial respiratory chain Complexes I – IV are particularly rich 
in transition metal-containing redox centers, with a complement of 21 
centers that include heme iron, copper, and [2Fe2S], [3Fe4S] and 
[4Fe4S] iron sulfur (FeS) clusters. Up to 18 of these adopt EPR-
detectable paramagnetic states in native mitochondria and are readily 
observed at temperatures close to liquid helium (10 – 40 K).69 The 
spin-Hamiltonian parameters, midpoint potentials and relaxation 
behavior of these centers have been reasonably well characterized,69–87 
along with some other tissue-specific signals from transferrin, 
ceruloplasmin, and catalase.88–90 Specific applications of EPR to 
mitochondria have included detection of an irreversible deficiency in 
Complex I FeS clusters in iron-deficient rats,91 heme-nitrosyl in 
substantia nigra of Parkinson’s diseased brain,92 chromium-dependent 
inhibition of Complexes I & II and aconitase,93 cardio- and neuro-
protection against doxorubicin,80 prophylaxis against 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine in a Parkinson’s mouse model,82 the 
differential sensitivity of aconitase and FeS clusters from Complexes I 
& III to oxidative and nitrosative stress in heart,94 and the sensitivity 
of Complex III FeS clusters in aging heart to ischemia.95 However, 
despite these successes in mechanistic studies, the authors are 
unaware of any direct application of EPR for functional 
pathophysiologic studies in humans or whole animal models with 
primary mitochondrial disease; the closest analog is a study in which a 
comparison of EPR signals from muscle biopsies of sepsis patients 
indicated significant depletion of Complex I FeS signals in those who 
died compared to survivors.86,96 
One group of MD that has been recently well-characterized and 
suggests itself as a promising model for evaluation of new 
pathophysiologic methodologies is the mitochondrial DNA (mtDNA) 
depletion syndromes (MDS). MDS comprises a genetically and clinically 
heterogeneous group of autosomal recessive diseases characterized by 
a reduction in tissue-specific mtDNA copy number. This reduction is a 
result of molecular defects in either the genes responsible for mtDNA 
biogenesis, or those required for the maintenance of deoxynucleotide 
pools or mtDNA integrity.97–99 The loss of mtDNA can lead to a variety 
of clinical presentations that are dependent on the gene involved and 
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the nature of the mutation. Depletion of mtDNA is the most common 
cause of multi-systemic oxidative phosphorylation defects,100 with 
deoxyguanosine kinase (DGUOK) deficiency being the most frequent 
cause. Death commonly results from liver failure,26,97,101,102 which may 
occur in the context of natural disease progression, exposure to 
sodium valproate103–105 or complications of viral infections such as 
influenza.55,106 Less severe attenuation of DGUOK function may result 
in a susceptibility to isolated liver failure97,107,108 or a myopathic 
presentation of DGUOK deficiency.109 Some cases with milder 
mutations have required liver transplantation, with its attendant 
complications, and may subsequently develop myopathy.97,108 Over the 
preceding 5 years, we have developed an accurate method for assay 
of tissue-specific mitochondrial DNA content using quantitative real-
time polymerase chain reaction (qPCR) that has led to accurate 
retrospective modeling and prospective diagnosis of patients with 
hepatic mtDNA depletion.55,110–116 This is accepted as the clinical 
standard for diagnosis of mtDNA depletion.54 The development of a 
robust diagnosis for MDS and the detailed characterization of DGUOK 
deficiency, in particular, suggested to us that an animal model of 
DGUOK deficiency would be of great value in developing and 
evaluating the potential of new diagnostic and pathophysiologic 
techniques for MD. 
In the present work, we aim to introduce EPR of tissue samples 
at cryogenic temperatures as a mechanistic tool for MD. We have 
developed a rat model of DGUOK deficiency (referred to by the trivial 
name “DGUOK”) that exhibits characteristic biomarkers, and we have 
applied standard biochemical and pathological tests along with EPR. 
The goals of this work are to characterize the DGUOK rat in terms of 
mitochondrial dysfunction and pathological outcome, and to evaluate 
EPR as a new and additional technique in an integrated 
characterization of MD. 
Materials and Methods 
The DGUOK rat model of DGUOK deficiency 
Previously described zinc-finger nuclease (ZFN) technology was 
employed.117,118 A preferred binding/cutting site of 
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GTCGGTTCCTTCTGCgtagacTCCGAGCGTCTTTCCG was identified from a 
clinically relevant transcript of DGUOK and the appropriate ZFN was 
obtained from Sigma Aldrich (CompoZr Custom ZFN Service). This was 
injected into the pronucleus of a fertilized one-cell embryo. These 
microinjected embryos were then implanted into a “pseudo-pregnant” 
recipient female rat. This resulted in the generation of four 
characterized DGUOK rat knockout lines named SSdguokM1 SSdguokM2 
SSdguokM3 and SSdguokM4. Because of the rare potential for an off-target 
effect, where ZFNs cause double-strand breaks and mutations at 
undesired loci, we backcrossed and bred homozygote animals from 
these two lines.117 The “M1” line has a 31 base pair deletion after 
amino acid six leading to a premature stop codon, i.e., a polypeptide 
with 34 amino acids (the first 6 from the original protein sequence and 
28 from the missense). Similarly, the “M2” line has a 37 base pair 
amino acid deletion after amino acid six. This frame-shift mutation 
would lead to a 42 amino acid polypeptide with only the first 6 amino 
acids consistent with the original protein sequence. 
The M3 line had a net 57bp frameshift deletion in exon 1 
including the initiation codon which is predicted to lead to the use of 
an alternate start codon in exon 1 with a 5′ truncated protein devoid of 
the mitochondrial targeting sequence. The M4 line had an in-frame 
deletion of 9 nucleotides in the targeting sequence. This strain does 
not have hepatic mtDNA depletion and, because of the adequacy of 
the first two models, was not further characterized. 
The generation of the animal model and all subsequent animal 
experiments were performed under approved Animal Use Application 
by the Institutional Animal Care and Use Committee (IACUC) of the 
Medical College of Wisonsin (protocols 2214 and 1764, respectively). 
mtDNA assay 
Real time analysis was performed as previously published and 
validated in humans55,97,112 using rat specific primers. DNA was 
extracted using Qiagen Blood Core Kit #158389 and quantified using 
the Quant-iT PicoGreen double stranded DNA kit (Invitrogen) and a 
Varioskan plate reader (Thermo Fisher) in 96 well format. DNA is 
diluted to a concentration falling with in efficiency range of the assay 
0.125–4 ng/l. qPCR was carried out on 10 μl samples, each containing 
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between 0.35 and 12 ng of extracted DNA, 5 pmol of each forward and 
reverse primer, and 5 μl iTAQ SYBR Green Supermix with ROX 
(BioRad). The mitochondrial genome-targeted rat-specific primers 
used were tRNALeu F: GGTTATTAGGGTGGCAGAGC and tRNALeu 
R:GGAAGGCCATGGCAATTAAG. Nuclear primers, targeted to the ActB 
coding region, were ActB F:TACCACTGGCATTGTGATGG and ActB R: 
ACGCTCGGTCAGGATCTTC. The Basic Local Alignment Search Tool 
(National Center for Biotechnology Information) was used to show that 
primers hybridized to unique sequences in Rattus norvegicus. The real-
time qPCR cycling conditions were (i) 50°C for 2 min, (ii) 95°C for 10 
min, (iii) 45 cycles of 15 seconds at 95°C, and (iv) a combined 62°C 
anneal/extension for 30 seconds. Upon completion of 45 cycles, a pre-
programmed dissociation step was carried out by one cycle of 95°C for 
15 seconds, 50°C for 15 seconds and 95°C for 15 seconds. Real-time 
fluorescence was measured and analyzed on a 7900HT Fast Real-Time 
PCR system (Applied Biosystems, Foster City, CA) using SDS V2.3 
software. All samples were assayed in triplicate. The relative mtDNA 
copy number was determined from the threshold difference between 
the averages of each set of triplicate reactions. 
Histology 
A portion of each heart, lung, liver, spleen, and kidney from 4 
wild-type SS rats and 5 SSdguokM2DGUOK rats at 11 months of age was 
fixed in formalin for histological analysis. Fixed tissue was paraffin-
embedded, sectioned, and stained with hematoxylin and eosin (H&E) 
using standard techniques. To evaluate possible liver fibrosis, sections 
of liver were also stained using Masson trichrome stain using standard 
techniques. For evaluation of muscle pathology, a quadriceps muscle 
from each animal was frozen in isopentane at −78.5 °C, and 8 μm 
cryosections were stained for H&E, Gomori trichrome, reduced 
nicotinamide adenine dinucleotide (NADH), cytochrome oxidase (COX), 
and succinate dehydrogenase (SDH) using standard techniques. 
Protein immunoblot (western blot) 
Protein homogenates prepared from the quadriceps muscle were 
evaluated for mitochondrial electron transport chain complex 
expression using standard western blot techniques.119 Transferred 
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proteins were probed with a MitoProfile Total OXPHOS Blue Native WB 
Antibody Cocktail (MitoSciences #MS603, Abcam, Cambridge, MA), 
which includes antibodies against mitochondrial respiratory chain 
complexes I–V, and visualized using enhanced chemiluminescence. 
Quantification was performed using ImageJ version 1.44p and 
statistics were evaluated using Student’s t-test. 
Electron transport chain activity assay 
Electron transport chain activity assays were carried out on 
frozen rat muscle and liver (n = 6 for controls and n = 5 for DGUOK 
rats) according to protocols previously described in detail120,121 with the 
modification that the linear initial velocity in the first minute was 
determined for Complex III, instead of a formal rate constant, due to 
the lower activity compared to Complexes I, II and IV. The activities of 
Complexes I – IV were normalized for mitochondrial content by 
dividing by citrate synthase activity. The results of electron transport 
chain activity assays are not normally distributed but become so after 
transformation to their natural logarithms. Results are expressed as 
average values and the standard error of the mean. Significance is 
expressed by the non-parametric Mann-Whitney U test on the raw 
data and by Student’s t-test of the logarithmically transformed data. 
Blue native PAGE analysis with in-gel activity staining was carried out 
as previously described.121–123 This allowed the identification of 
decreased synthesis of mitochondrial subunits.124 
EPR spectroscopy 
Fresh tissue samples for EPR were rapidly extruded into 3 mm 
diameter EPR tubes and frozen in liquid nitrogen within 90 s of harvest 
(we have found that tissue can be frozen much more rapidly than 
dilute aqueous solutions and with much reduced risk of the EPR tube 
breaking). Samples entirely filled the active length of the EPR 
resonator. EPR spectra were recorded on a Bruker EleXsys E600 
spectrometer equipped with a Super-X microwave bridge with 
integrated microwave counter, an ER4112SHQ resonant cavity 
operating at 9.38 GHz, and an Oxford Instruments ESR900 helium flow 
cryostat and ITC503 temperature controller. Spectra were recorded 
with 10 G magnetic field modulation at 100 kHz and this modulation 
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amplitude determined the spectral resolution. Microwave powers and 
temperatures are given in the figure legends. Scans of 4096 points, 
8000 G field envelope and 3 min duration were averaged over 60 – 
180 min to provide the final spectrum. A background spectrum 
collected on frozen water was subtracted from rat tissue spectra. 
Experimental spectra were modeled by fitting a library of computed 
spectra corresponding to the mitochondrial respiratory chain centers 
and the [3Fe4S] cluster of aconitase,69 using a Levenberg-Marquardt 
algorithm to minimize χ2 (IGOR Pro v. 6.32A, Wavemetrics, Lake 
Oswego, OR). The contributions of each component were constrained 
to ≥ 0. Correlation matrices indicated strong interdependencies 
(correlation coefficients ~ 0.7) of contributions from the pairs of 
signals (i) Complex II S3 3Fe4S and aconitase 3Fe4S, and (ii) Complex 
I N1b and N2 FeS clusters. N1b and N2 could not be deconvoluted and 
only the overall contribution from N1b + N2 is given, whereas S3 and 
aconitase were deconvoluted by the use of two temperatures.69 
Computed spectra of the individual components were calculated with 
XSophe (Bruker Biospin;125,126) using spin Hamiltonian parameters 
from the literature,69–79 and computed spectra were normalized for the 
intensity of ∫χ″.dH (i.e. the first integral of the EPR absorption, or so-
called “double-integrated spectrum”) prior to fitting to the 
experimental data. 
Results 
Recapitulation of mtDNA depletion in DGUOK rat 
To evaluate the phenotype, three M2, four M1 and six SS 8-
week-old females were sacrificed and tissue harvested. DNA was 
extracted and subject to qPCR evaluation using validated rat-specific 
primers, but otherwise as previously described.112 This method 
demonstrates an approximately 90% reduction in hepatic mtDNA 
content (Figure 1). This reduction is similar to the 80–90% reduction 
in hepatic mtDNA seen in humans with this disorder.112 Similarly, a 
60–80% reduction in splenic DNA content was observed.100 The 
situation was less clear in muscle; while M1 rats exhibited about 60 % 
depletion in mtDNA, the mtDNA level in the M2 rat was 
indistinguishable from that in wild-type. Consequently mtDNA content 
was assessed in sections of the same tissue that was used for 
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Histology, ETC and EPR assays. This demonstrates no significant 
difference in mtDNA content in skeletal muscle, regardless of 
predominant oxidative fiber type (Table S1). 
 
Figure 1: Absolute mtDNA content in DGUOK rats 
The mtDNA copy numbers for eight week old M1 and M2 DGUOK knockout rats 
compared with wild-type (SS) rats. The error bars indicate standard deviations for n = 
6 (SS), n = 4 (M1) and n = 3 (M2). 
Pathology of the DGUOK rat 
A pathological analysis was performed on 4 wild-type and 5 
DGUOK rats at approximately 11 months of age, including the 
histological evaluation of heart, lung, liver, spleen, kidney, and 
muscle. H&E-stained sections of heart, lung, liver, spleen, and kidney 
revealed no apparent differences in the organ histology when 
comparing wild-type and DGUOK rats. Liver fibrosis was further 
evaluated using Masson trichrome staining, which also showed no 
evident differences between wild-type and DGUOK livers. In contrast, 
there were marked differences on oxidative enzyme staining when 
comparing the quadriceps muscles of wild-type and DGUOK rats 
(Figure 2). While pathological differences were not apparent on H&E 
staining, there were numerous fibers that showed negative staining on 
both cytochrome oxidase (COX) and succinate dehydrogenase (SDH) 
stains (Figure 2). Large numbers (up to 20–30% of fibers) of these 
COX negative/SDH negative fibers were seen in all DGUOK rats, 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Free Radical Biology and Medicine, Vol 92 (March 2016): pg. 141-151. DOI. This article is © Elsevier and permission has 
been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this article 
to be further copied/distributed or hosted elsewhere without the express permission from Elsevier. 
13 
 
whereas they were essentially absent in all of the wild-type rat 
muscles examined. 
 
Figure 2. Skeletal muscle pathology in 11 month old WT and DGUOK rats 
Quadriceps muscles from DGUOK rats display little differences on H&E staining in 
comparison to WT littermates. In contrast, staining for COX and SDH reveals 
numerous fibers in DGUOK rat muscle that are negative for both COX and SDH, 
whereas no such fibers were evident in WT rat muscle. The bar at the bottom, right 
corresponds to 200 μm. 
Expression of respiratory chain complexes 
Mitochondrial protein expression was found to be altered in 
quadriceps muscle of the 11 month old DGUOK rat (Figure 3). 
Specifically, the data indicated that Complex I was significantly under-
expressed (54 % of wild-type; p = 0.05) and suggested that Complex 
III was also under expressed (47 % of wild-type; p = 0.12). The 
expression levels of Complexes II, IV & V were unchanged in DGUOK 
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rat muscle. Varying, though generally low, amounts of an unidentified 
immunoreactive protein with Mr ≈ 30 kDa were also observed. 
 
Figure 3. Respiratory chain complex expression in DGUOK rat muscle 
Western blots of mitochondrial electron transport chain complexes I–V and GAPDH 
from stripped membranes of quadriceps muscle from 11 month old wild-type and 
DGUOK rats are shown in the top panel. The results of quantitation of the respiratory 
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chain complex bands are shown below, normalized for GAPDH expression. The error 
bars indicate standard errors for n = 4. 
Electron chain transport assays 
Significantly lower activities for Complexes I, III and IV were 
observed in DGUOK rat liver, corresponding to about 20 %, 7 % and 
13 % of wild-type activity, respectively, whereas Complex II activities 
were statistically indistinguishable (Figure 4, Table 1). In DGUOK 
muscle, the activities of Complexes I and III were only 9 % and 20 % 
of wild-type, respectively, whereas Complex II and IV activities were 
essentially indistinguishable. 
 
Figure 4. Electron transport chain functional assays of Complexes I– IV 
The functional activities of Complexes I – IV from liver and quadriceps muscle of 
DGUOK rat are shown, normalized for mitochondrial content (as citrate synthase 
activity) and expressed as percentages of activities from wild-type. Detailed results 
are given in Table 1 (or S1). 
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Table 1. Results of electron transport chain assays of Complexes I – IV from 




1000 × Wild-type 
activity ÷ citrate 
synthase activity 
1000 × DGUOK 









    
Complex I 230.08 ± 18.81 47.64 ± 9.53 0.008 0.002 
Complex 
II 
991.9 ± 95.3 1291.6 ± 258.3 0.522 0.250 
Complex 
III 
14.35 ± 0.80 1.02 ± 0.20 0.008 0.001 
Complex 
II – III 
430.1 ± 32.6 129.3 ± 25.9 0.029 0.012 
Complex 
IV 
137.54 ± 11.69 17.70 ± 3.54 0.014 0.002 
MUSCLE 
    
Complex I 108.1 ± 8.25 9.73 ± 4.25 0.008 0.015 
Complex 
II 
278.1 ± 16.42 215.8 ± 18.41 0.522 0.093 
Complex 
III 
3.43 ± 0.48 0.70 ± 0.18 0.036 0.025 
Complex 
II –III 
263.7 ± 28.53 157.6 ± 15.36 1.00 0.070 
Complex 
IV 
38.63 ± 5.60 53.93 ± 8.76 0.412 0.434 
EPR spectroscopy 
The EPR spectra at 12 K of liver, quadriceps muscle and heart 
from wild-type and DGUOK rats are shown in Figure 5. The signals are 
complex but some features are immediately identifiable and are 
labeled a – k in Figure 5. Feature a at g′ ~ 6 is due to high-spin 
ferriheme; b at g′ ~ 4 is due largely to Fe(III) in transferrin; a 
complex pattern extending upfield from c is due to Mn(II), which is 
prominent in liver but much less so in quadriceps muscle and not 
detectable in heart, and overlaps the signals from the respiratory chain 
iron sulfur clusters; the prominent feature at d is the so-called “g = 
2.01” signal and is due to overlapping signals from the oxidized 3Fe4S 
clusters of Complex II and oxidatively-damaged aconitase; the signal 
at e, the so-called “g = 1.94” signal, is due to overlapping g2 
resonances from reduced 2Fe2S and 4Fe4S clusters, primarily those 
from Complex I; the signals at f are the g3 resonances from Complex I 
N4 4Fe4S (lower field) and Complex I N3 2Fe2S (higher field) and are 
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overlaid on the highest field mI = 5/2 resonance of the mS = ½ 
manifold of S = 5/2 Mn(II) (the latter is not clear in trace A but much 
more pronounced in trace B); the resonances labeled g are gx and gy 
of the rhombic high-spin ferriheme of catalase;88 the resonances 
around h are due to low-spin ferriheme; feature i is the g1 (gx) 
resonance of low-spin heme a of Complex IV; and k indicates the g1 
(gx; lower field) and g3 (gz; higher field) resonances from the Rieske 
2Fe2S cluster of Complex II. The broad EPR absorption in the liver 
spectra from about 2000 G is largely due to rapid-passage of the 
Mn(II) leading to an absorption-like signal that includes components 
from the mS = 3/2 and mS = 5/2 manifolds,127 along with some 
contribution from CuA of Complex IV. 
 
Figure 5. 12 K EPR spectra from wild-type and DGUOK rat tissue 
The spectra are from samples of A, wild-type rat liver; B, DGUOK rat liver; C, wild-
type rat quadriceps muscle; D, DGUOK rat quadriceps muscle; E, wild-type rat heart; 
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and F, DGUOK rat heart. In each case, the sample completely filled the part of the EPR 
tube that occupied the active region of the resonator. A & B shown × 1, C & D are 
shown × 2, and E & F shown × 0.5. Spectra were recorded at 12 K, 2.5 mW power. 
The lower-case labels identify specific signals in the spectra: (a) high-spin axial 
ferriheme g⊥; (b) transferrin non-heme Fe(III); (c) the mI = 5/2 line at the low-field 
extremity of the six-line Mn(II) hyperfine pattern; (d) overlapping signals from 
aconitase and S3 [3Fe4S] clusters; (e) overlapping g2 resonances from Complex I 
[2Fe2S] and [4Fe4S] clusters; (f) resolved g3 resonances from N4 and N3 clusters; (g) 
high-spin catalase gx and gy lines; (h) low-spin catalase resonances; (i) heme a g1; 
and (k) Rieske [2Fe2S] cluster g1 and g3 resonances. 
Visual inspection of the spectra provides some limited 
information. Mn(II) is clearly elevated in DGUOK liver whereas the 
reduced Complex I FeS signals (e, f) are diminished. In DGUOK 
quadriceps muscle, the Complex I FeS signals and the Complex III 
Rieske signals are markedly diminished compared to wild-type. In both 
muscle and liver, the g = 2.01 signal (d) due to Complex II S3 and/or 
aconitase appears elevated in DGUOK compared to wild-type. To 
further investigate this phenomenon, spectra were recorded at 40 K 
(Figure 6) where the faster-relaxing S3 signal intensity is lowered 
relative to the more slowly relaxing aconitase signal. In liver, the 
difference in intensity of the g = 2.01 signal persists and we assign 
this as being due to a 25 % increase in the aconitase signal in DGUOK 
over wild-type. In quadriceps muscle at 40 K, the DGUOK signal is now 
smaller than the wild-type signal, indicating that the difference at 12 K 
is due to elevated amounts of oxidized Complex III S3 3Fe4S. Clear 
signals due to g1 (gx) of heme a of Complex IV were only observed in 
heart. The signals in liver and quadriceps were much broader and 
suggestive of a distribution of g-values; this resonance position of this 
signal was found to be very sensitive to mutations in bacterial 
cytochrome c oxidase128 and the apparent distribution of g1 values may 
reflect multiple environments in liver mitochondria. In liver, the signal 
from transferrin was elevated and that from catalase was depressed. 
Interestingly, no significant differences at all were observed between 
the EPR spectra of heart from wild-type and DGUOK rats. 
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Figure 6. 40 K EPR spectra from wild-type and DGUOK rat tissue 
The spectra are from samples of A, wild-type rat liver (solid line) and DGUOK rat liver 
(dashed line); and B, wild-type rat quadriceps muscle (solid line) and DGUOK rat 
muscle (dashed line). Spectra were recorded at 40 K, 2.5 mW power. 
For quantitative information we turned to computer simulation 
of the spectra. Figure 7 shows the g ~ 2 region of the experimental 
spectra for liver (A, B), quadriceps muscle (E, F) and heart (I, J) from 
DGUOK and wild-type rats. In each case, fits to the library of 
computed spectra were generated. As we are particularly interested in 
the differences between wild-type and DGUOK, difference spectra 
(DGUOK minus wild-type) of the experimental data (C, G and K for 
liver, muscle and heart, respectively) and the computed fits (D and H 
for liver and muscle; no significant difference was observed between 
the fits to wild-type and DGUOK heart) are presented. The 
experimental and computed difference spectra match very well and 
details of the fits are given in Table 2/Table S2. From the fit 
parameters, and using the dual temperature study to resolve the S3 
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and aconitase 3Fe4S contributions, we calculated the fractional 
difference between the intensities of each of the components in the 
DGUOK and wild-type tissues, and the significant results are 
summarized in Figure 8. 
 
Figure 7. Quantitative analysis of the 12 K EPR signals from wild-type and DGUOK rat 
tissues 
Traces A, B, E, F, I and J show the g′ ~ 2 region of the EPR spectra of A, wild-type rat 
liver; B, DGUOK rat liver; E, wild-type rat quadriceps muscle; F, DGUOK rat 
quadriceps muscle; I, wild-type rat heart; and J, DGUOK rat heart. Trace C is the 
difference spectrum obtained by subtraction of A from B, and is shown multiplied by a 
factor of two; likewise, G = 2×(F − E) and K = 2×(J − I). Trace D is a theoretical 
simulation of C generated by the subtraction of fits of A and B to model spectra of the 
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paramagnetic species likely to be observed in the mitochondrion. Fitting parameters 
are presented in Table 2 (or S2). Similarly, trace H is a simulation of J from fits to E 
and F. No attempt was made to simulate K, as no significant differences were 
observed between fits to I and J. 
 
 
Figure 8. Summary of EPR of DGUOK rat liver and muscle 
A comparison of signal intensities is shown for some of the respiratory complex redox 
centers in liver and muscle from the DGUOK and wild-type rat. The standard errors 
were calculated from those of the fit parameters, presented in Table 2 (or S2). 
 
Table 2. Fitting parameters for the EPR signals from spectra of liver and 
muscle tissue from wild-type and DGUOK rats. The absolute intensities of 
each species (or group of species) are shown for wild-type and DGUOK, along 
with the percentage differences between DGUOK and wild-type intensities in 
brackets 
EPR Signal Liver 
W/T 




Muscle DGUOK [Δ 
(%)] 
Heartb 
CuA 47 ± 13 44 ± 15 [NS]c 9 ± 1 13 ± 1 [+45] NDd 
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EPR Signal Liver 
W/T 




Muscle DGUOK [Δ 
(%)] 
Heartb 
Heme a 200 ± 50 100 ± 60 [−50] ND ND 200 ± 30 
High-spin heme 116 ± 7 71 ± 9 [−39] 44 ± 1 31 ± 1 [−30] 183 ± 3 
N1b + N2 26 ± 5 16 ± 5 [−39] 28.2 ± 0.2 7.4 ± 0.5 [−74] 111 ± 1 
FeS N3 17 ± 8 8 ± 5 [−53] 16 ± 1 5.5 ± 0.7 [−61] 38 ± 4 
FeS N4 41 ± 8 20 ± 6 [−51] 33 ± 1 14 ± 1 [−59] 108 ± 4 
All Complex I 
FeS 
84 ± 12 44 ± 9 [−49] 77 ± 1 26 ± 1 [−66] 257 ± 6 
S3 + Acn 10.8 ± 
1.6 
15 ± 2 [+37] 1.3 ± 0.1 3.8 ± 0.1 [+192] 17 ± 1 
FeS S1 27 ± 10 29 ± 13 [NS] 15 ± 1 8 ± 1 16 ± 5 
FeS S2 ND ND ND ND 60 ± 5 
S1 + S2 27 ± 10 29 ± 13 [NS] 15 ± 1 8 ± 1 [−48] 76 ± 7 
Rieske FeS 99 ± 11 98 ± 12 [NS] 37 ± 1 18 ± 1 [−51] 238 ± 5 
Mn(II) 295 ± 27 588 ± 32 [+99] 32 ± 3 20 ± 2 [−35] ND 
aCalculated as {[(DGUOK signal) − (wild-type signal)] ÷ (wild-type signal)}×100. 




The aims of this work are to describe the DGUOK rat 
mitochondrial phenotype and evaluate it as a model for mitochondrial 
disease, and to apply EPR spectroscopy of tissue to enable an 
understanding of what happens at the electron level in tissue with 
mtDNA depletion. The DGUOK rat has a complex and tissue-dependent 
mitochondrial phenotype. The DGUOK liver exhibited markedly lower 
mtDNA copy number, ~ 10 % of wild-type. However, EPR showed that 
Complex I FeS clusters were present at least 50 % as much as in wild-
type, and signals from S1, S2, S3 and the Rieske FeS clusters 
indicated that Complexes II and III are expressed at the same level as 
in wild-type. The observation that the four EPR-detectable FeS cluster 
signals are depleted by the same amounts, despite very different 
redox potentials, and that signal intensities from both the S1–S2 pair 
and the Rieske cluster are indistinguishable from wild-type suggests 
that (i) the lowered Complex I signals are due to depressed expression 
or Fe incorporation, rather than an elevated redox potential, and (ii) 
the depleted Complex I complement therefore provides sufficient 
electrons to load the electron transfer chain. The aconitase 3Fe4S 
signal, a characteristic marker for oxidative stress,82 was elevated in 
DGUOK liver. Also, Mn(II), which is present at high levels in wild-type 
liver and is proposed to be additionally generated in response to 
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oxidative stress,127 was doubled compared to wild-type. The activities 
of Complexes I, III and IV in DGUOK liver were very depressed 
compared to wild-type, and by far more that can be accounted for by 
expression levels. It is tempting to speculate that the oxidative stress 
identified by the aconitase and Mn(II) EPR signals is either a cause or 
consequence of the additional Complex I, II and IV dysfunction in 
DGUOK liver. The very low levels of Complexes III and IV activities 
explain the EPR observation that the electron transfer chain remains 
electron-rich, and the redox potential maintained close to the 
NADH:NAD midpoint potential, even though Complex I activity is also 
significantly depressed. The elevation of the EPR signal from 
transferrin may indicate some hemorrhaging, and the depression of 
the catalase signal also suggests some disease or damage to the 
liver.129 
The mitochondrial phenotype in DGUOK quadriceps muscle is 
also complex. Consistent with muscle evaluated in humans with severe 
disease, protein expression levels for Complexes I and III were also ~ 
50 % of wild-type, whereas Complexes II, IV and V were expressed at 
wild-type.108 However, in contrast to humans with severe disease, the 
mtDNA copy numbers for wild-type and M2 DGUOK were similar across 
all muscle groups [table S1]. This lack of difference in the muscle 
types may reflect variability in sampling, the milder phenotype in the 
rats or an underlying correction in muscle tissue for example by de 
novo purine synthesis or alternate salvage pathways. This data 
underscores the limited sensitivity of qPCR previously described in 
human muscle112 and emphasizes the need to consider evaluation of 
liver specifically for depletion in this disease. 
Consistent with protein expression levels, EPR of DGUOK 
quadriceps muscle indicated that Complex I is present at ≥ 35 % of 
the wild-type level and Complex III at about 50 %. The EPR data for 
Complex II are revealing. The S3 cluster signal was twice as intense as 
in wild-type, yet the S1 and S2 clusters were diminished by a factor of 
two. This could indicate a catastrophic inability to correctly assemble 
Complex II or incorporate S1 and S2 but this would be expected to 
essentially abolish activity, and the elevation of S3 would require a 
doubling of Complex II expression. Neither phenomenon was 
observed. More likely, the changes in S1, S2 and S3 reflect a Complex 
II that experiences a significantly more oxidizing redox potential than 
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in wild-type mitochondria. This hypothesis is strongly supported by the 
very low Complex I electron transferring activity compared to the 
downstream activities of Complexes II, III and IV. Therefore, Complex 
II is drained of electrons and produces the EPR signature observed in 
DGUOK quadriceps muscle. This scenario also explains the lack of 
markers for oxidative stress in the EPR signature of DGUOK muscle. In 
the absence of Complex I activity, very few electrons enter the 
respiratory chain to begin with. Furthermore, the downstream 
components are in a more oxidized state and thus are primed to 
receive any electrons that do enter the respiratory chain, essentially 
acting as antioxidants. So, while Complex III dysfunction results in 
electron buildup and oxidative stress in DGUOK liver, the lack of 
activity of Complex I and downstream oxidation of Complexes II – IV 
in muscle does not result in oxidative stress even though Complex III 
activity is as depressed in muscle as it is in liver. The only EPR marker 
observed for Complex IV in this study, the heme a signal, was very 
weak and broad in muscle and was not significant in the fits. 
Nevertheless, visual examination suggests a comparable signal in wild-
type and DGUOK, consistent with the significant Complex IV activity. 
What remains unclear is the reason(s) behind the low activities of 
Complexes I and III. Native PAGE provides no evidence for subunit 
depletion, and EPR does not indicate oxidative stress. 
In contrast to liver and quadriceps muscle, the heart in the 
DGUOK rat appears entirely unaffected. The mtDNA copy numbers are 
normal and the EPR signals of wild-type and DGUOK heart are 
indistinguishable themselves and very similar to wild-type quadriceps 
muscle. Large EPR signals from Complex I N3 and N4, a large signal 
from Complex III Rieske 2Fe2S, a high ratio of the g = 1.94 and g = 
2.01 signals, and a weak signal from Complex IV heme a all indicate a 
very reducing environment that is consistent with an active Complex I 
and a fully functioning respiratory chain that does not produce 
oxidative stress. 
EPR is a unique tool in that it can interrogate the status of the 
mitochondrion at the time of freezing, in unprocessed viable biological 
samples. First, it is clear that in both liver and quadriceps muscle, EPR 
identified mitochondrial dysfunction in the DGUOK rat. Second, some 
mechanistic information on the DGUOK rat was obtained. In liver, the 
EPR results indicated that the reduced electron transfer chain activity 
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of Complexes I is in part due to reduced expression but that the very 
low activity of Complex, III is not a consequence of reduced 
expression or Fe incorporation as FeS clusters. The retention of the 
Complex III Rieske 2Fe2S EPR signal in DGUOK liver indicates that 
Complex III is present at wild-type levels, incorporates the Rieske 
cluster, and electrons can progress through the respiratory chain at 
least as far as the Rieske cluster. The reason for Complex III inactivity 
remains unknown but appears to be downstream of the Rieske cluster. 
Oxidative stress may be important, and two independent markers for 
oxidative stress were identified, elevated aconitase 3Fe4S and Mn(II); 
two markers for liver damage were also identified, depressed catalase 
and elevated transferrin. In quadriceps muscle, EPR provides 
complementary information to the activity assays. The lack of Complex 
I activity and the EPR identification of oxidation of the three Complex 
II FeS clusters provides a rationale for the lack of any EPR markers for 
oxidative stress in muscle. A knowledge of whether oxidative stress is 
a consequence of mitochondrial disease, and in which tissues and why, 
is an important piece of information that may inform therapy choices. 
Conclusions 
The DGUOK rat capitulates major biochemical features observed 
in humans with DGUOK deficiency, specifically significantly reduced 
mtDNA content, reduced mitochondrial complex I, III and IV protein 
content and enzymatic activity in frozen liver. EPR assessment of 
flash-frozen tissues has demonstrated dramatic differences in the 
mitochondrial electron transport chain status in situ compared with 
wild-type animals. The reproducibility and magnitude of these 
differences is encouraging given the relatively mild pathologic 
differences seen in the animals. It suggests that EPR may be able to 
reliably distinguish individuals with mitochondrial disease from distinct 
etiologies of muscle or liver disease in humans. 
Highlights 
• A rat model of DGUOK deficiency approximates the human disease 
• EPR is sensitive for detecting mitochondrial functional abnormality 
in situ. 
• EPR shows how the respiratory chain is affected by mitochondrial 
disease. 
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• EPR has a role in mechanistic pathophysiological studies of 
mitochondrial disease 
• There is strong potential for EPR as an additional diagnostic tool. 
Abbreviations 
COX cytochrome oxidase 
M2 deoxyguanosine kinase-deficient rat model 
DGUOK deoxyguanosine kinase 
EPR 
(ESR) 
electron paramagnetic (spin) resonance 
FeS iron-sulfur (cluster) 
H&E hematoxylin and eosin 
MD mitochondrial disease 
MDS mitochondrial DNA depletion syndrome 
MPV17 mitochondrial inner membrane protein 
mtDNA mitochondrial DNA 
NADH reduced nicotinamide adenine dinucleotide 
POLG DNA polymerase γ 
SDH succinate dehydrogenase 
TWINKLE 
a mitochondrial DNA helicase encoded by chromosome 10, open 
reading frame 2 (also known as C10orf2) 
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Replies to Reviewers. 
 
1. In the text (page 13, last paragraph) it stated that the temperature was 10 K while in the figure legend, says 12 K. 
 
The authors thank the reviewer for catching this error on line 17 of page 13 of the original submitted manuscript. 
The same error appeared on line 19 of page 12. The figure legends correctly state that the temperature in question 
was 12 K, and the manuscript has been amended to reflect this. 
 
 
2. What was the microwave power the authors used under 10 (12) K and 40 K respectively since the sample may 
saturate differently? 
 
The power at the two temperatures was the same, 2.5 mW, as stated in the legends to Figures 5 & 6. The point that 
the sample may saturate differently under different conditions is well taken; in fact, the differential response of 
distinct but overlapping signals with different (T1) relaxation times to potentially saturating conditions is precisely 
the phenomenon that is being exploited here for the deconvolution of the contributions of those signals. 
 
 
Page 13, 2nd paragraph, p = 0.12 seems a statistical insignificant result. Can authors comment on this result? 
 
The Graph was incorrectly numbered and labeled. The figure legend says that the error bars represent standard 
deviations whereas they really represent standard errors.  The variation in signal in the wild type animals was 
significantly great that the result was statistically insignificant. The figure legend has been corrected. 
 
4. Most important the assignment of c and e to Mn(II) (I = 5/2) is only 2 of the typical 6 line spectrum. Please explain. 
 
The Dguok spectrum, which is depleted in Complex I & II reduced FeS centers, actually shows features ascribable to 
most of the MI =  5/2, 3/2, and 1/2 lines forming the sextet of the MS =  1/2 Kramers' manifold [see e.g. the figure 
below showing a dotted model S = 5/2, I = 5/2 spectrum with zero-field splitting and hyperfine parameters typical of 
octahedral Mn(II), overlaid with the experimental spectrum of Dguok liver].  This is much less clear in WT, where 
the Mn(II) signal is much less intense and the FeS centers much more so. In the latter case, only the lowest field MS 
=  1/2, MI = 5/2 line (c) is clearly identifiable by its characteristic asymmetric shape (with a downfield "wing" due 
to underlying unresolved MS = 3/2, and 5/2 lines), although some overlap of the high-field line with the g3-
resonances of Complex I N4 and N3 (f) is evident to the keen observer. Because of the complexity of this region of 
the spectrum in all but the Dguok liver spectrum, we are reluctant to identify other lines as being due to Mn(II). 
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A novel rat model for a well-characterized human mitochondrial disease, mitochondrial DNA depletion 
syndrome with associated deoxyguanosine kinase (DGUOK) deficiency, is described. The rat model 
recapitulates the pathologic and biochemical signatures of the human disease. The application of electron 
paramagnetic (spin) resonance (EPR) spectroscopy to the identification and characterization of respiratory 
chain abnormalities in the mitochondria from freshly frozen tissue of the mitochondrial disease model rat is 
introduced. EPR is shown to be a sensitive technique for detecting mitochondrial functional abnormality in situ 
and, here, is particularly useful in characterizing the redox state changes and oxidative stress that can result 
from depressed expression and/or diminished specific activity of the distinct respiratory chain complexes. As 
EPR requires no sample preparation or non-physiological reagents, it provides information on the status of the 
mitochondrion as it was in the functioning state. On its own, this information is of use in identifying respiratory 
chain dysfunction; in conjunction with other techniques, the information from EPR shows how the respiratory 
chain is affected at the molecular level by the dysfunction. It is proposed that EPR has a role in mechanistic 
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COX, cytochrome oxidase; M2, deoxyguanosine kinase-deficient rat model; DGUOK, deoxyguanosine kinase; 
EPR (ESR), electron paramagnetic (spin) resonance; FeS, iron-sulfur (cluster); H&E, hematoxylin and eosin; 
MD, mitochondrial disease; MDS, mitochondrial DNA depletion syndrome; MPV17 mitochondrial inner 
membrane protein; mtDNA, mitochondrial DNA; NADH, reduced nicotinamide adenine dinucleotide; POLG, 
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DNA polymerase γ; SDH, succinate dehydrogenase; TWINKLE, a mitochondrial DNA helicase encoded by 
chromosome 10, open reading frame 2 (also known as C10orf2) 
 
  




 Mitochondrial disease (MD) occurs where depletion of mitochondrial DNA (mtDNA) or mutations in 
mtDNA and/or nuclear DNA (nDNA) lead to altered mitochondrial function.(1-4) Altered activities of Complexes 
I – V have been identified and physiological consequences of mitochondrial respiratory chain defects include 
reduced metabolic capacity, reduced ATP synthesis, and increased oxidative and nitrosative stress.(5-15) 
Symptoms of MD are manifold and include weakness (from central nervous system, peripheral nerve, and/or 
skeletal muscle disease), pain, intolerance of some general anesthetics and anti-epileptic drugs, 
gastrointestinal disorders, ophthalmoplegia and/or visual failure, failure to thrive, cardiac and respiratory 
disease, liver disease, diabetes, seizures, sensorineural hearing loss, mental retardation, dementia, movement 
disorders, increased susceptibility to infection, and pregnancy loss.(1, 2, 16-38) Establishing diagnoses and 
understanding the pathophysiology of mitochondrial disease (MD) has proven extremely challenging because 
of the extraordinary range of clinical symptoms and testing abnormalities (39). MD is often suspected in early 
childhood from clinical differential diagnosis of patients with diseases involving the brain, muscle, or liver. 
Traditional methods for diagnosing MD include clinical presentation, family history, pathology, metabolic 
profiling, enzyme activity levels, electrophysiology, magnetic resonance imaging (MRI) of brain and magnetic 
resonance spectroscopy (MRS) of metabolites, and mtDNA analysis (3, 7, 31, 40-53). Additional indicators 
include observation of mitochondrial proliferation, abnormalities on muscle histology (e.g., ragged red fibers or 
succinate dehydrogenase-positive fibers) (41, 54), and abnormalities in electron microscopy (46, 55). However, 
muscle histology may be normal despite the presence of biochemical abnormalities in the tissue. The 
determination of whether MD is present in a given patient can be extremely complex, given that (i) 
mitochondrial function can be secondarily affected due to the disease processes in non-mitochondrial diseases, 
(ii) there can be extensive variability in the distribution of abnormal mitochondria within an individual patient, 
allowing a “false negative” testing profile to occur when tissues with mitochondrial abnormalities are not tested, 
and (iii) there are no uniform, definitive pathological abnormalities that distinguish all MD patients from patients 
with other disorders. Diagnosis may ultimately rely on the application of diagnostic algorithms to predict the 
likelihood of MD  (56, 57) but MD is currently an under-diagnosed disease (4, 58-64). 
 Mechanistic information on MD has largely arisen from mitochondrial electron transport chain 
component activity assays on the components, isolated from their native matrix from fresh or frozen tissue, or 
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from cultured cells. These assays are, like most clinical biochemical assays, performed under non-physiologic 
basal conditions and with very different substrate concentrations than are seen in-vivo. Complex interactions 
between the substrates of these assays and other cellular components can lead to erroneous results (65) 
though these problems can, in principle be, overcome with careful isolation of proteins or in-gel assays. Assays 
of activities outside of the intact mitochondrial environment cannot identify defects in mitochondrial membrane 
potential or coupling. In clinical practice, it has been found that the methodological variations, limitations and 
difficulties associated with the use of respiratory chain functional assays as a diagnostic method for MD has 
led to massive inter-laboratory variability in results (66). In alternative approaches, substrates are added to 
whole cells or isolated mitochondrial preparations, and either oxygen consumption or ATP generation is 
measured [reviewed in (67)]. While recognized as the current standard for mitochondrial testing there are, 
again, significant limitations. Most apparent is the requirement for viable functioning mitochondria, requiring cell 
preparation or mitochondrial isolation and testing to be carried out temporally, and therefore geographically, 
proximate to the biopsy. The process of isolating mitochondria from native tissue risks damage and places the 
organelle outside of a truly physiologic condition. Conversely, whole cell assays require permeabilization of the 
cell to the substrates and transport to the mitochondria. The potentially limited ability to get reagents to the site 
of action can lead to a loss of sensitivity and specificity. In all of the currently employed assays, the 
mitochondrial function is not assessed in its native-organ context in the human and the need persists for an 
assay that measures the functional ability of mitochondria in an intact tissue preserved in a state as close as 
possible to that in situ.  
 Electron paramagnetic (spin) resonance (EPR, ESR) is a technique that can provide unique insight into 
mitochondrial status. EPR detects and characterizes free radicals and many transition metal ions and clusters 
in biological systems by measuring the magnetic field dependence of the absorption of microwave radiation at 
a given frequency by the unpaired electrons residing in these species (68). The mitochondrial respiratory chain 
Complexes I - IV are particularly rich in transition metal-containing redox centers, with a complement of 21 
centers that include heme iron, copper, and [2Fe2S], [3Fe4S] and [4Fe4S] iron sulfur (FeS) clusters. Up to 18 
of these adopt EPR-detectable paramagnetic states in native mitochondria and are readily observed at 
temperatures close to liquid helium (10 - 40 K) (69). The spin-Hamiltonian parameters, midpoint potentials and 
relaxation behavior of these centers have been reasonably well characterized (69-87), along with some other 
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tissue-specific signals from transferrin, ceruloplasmin, and catalase (88-90). Specific applications of EPR to 
mitochondria have included detection of an irreversible deficiency in Complex I FeS clusters in iron-deficient 
rats (91), heme-nitrosyl in substantia nigra of Parkinson's diseased brain (92), chromium-dependent inhibition 
of Complexes I & II and aconitase (93), cardio- and neuro-protection against doxorubicin (80), prophylaxis 
against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in a Parkinson's mouse model (82), the differential 
sensitivity of aconitase  and FeS clusters from Complexes I & III to oxidative and nitrosative stress in heart (94), 
and the sensitivity of Complex III FeS clusters in aging heart to ischemia (95). However, despite these 
successes in mechanistic studies, the authors are unaware of any direct application of EPR for functional 
pathophysiologic studies in humans or whole animal models with primary mitochondrial disease; the closest 
analog is a study in which a comparison of EPR signals from muscle biopsies of sepsis patients indicated 
significant depletion of Complex I FeS signals in those who died compared to survivors (86, 96). 
 One group of MD that has been recently well-characterized and suggests itself as a promising model 
for evaluation of new pathophysiologic methodologies is the mitochondrial DNA (mtDNA) depletion syndromes 
(MDS). MDS comprises a genetically and clinically heterogeneous group of autosomal recessive diseases 
characterized by a reduction in tissue-specific mtDNA copy number. This reduction is a result of molecular 
defects in either the genes responsible for mtDNA biogenesis, or those required for the maintenance of 
deoxynucleotide pools or mtDNA integrity (97-99). The loss of mtDNA can lead to a variety of clinical 
presentations that are dependent on the gene involved and the nature of the mutation. Depletion of mtDNA is 
the most common cause of multi-systemic oxidative phosphorylation defects (100), with deoxyguanosine 
kinase (DGUOK) deficiency being the most frequent cause. Death commonly results from liver failure (26, 97, 
101, 102), which may occur in the context of natural disease progression, exposure to sodium valproate (103-
105) or complications of viral infections such as influenza (55, 106). Less severe attenuation of DGUOK 
function may result in a susceptibility to isolated liver failure (97, 107, 108) or a myopathic presentation of 
DGUOK deficiency (109). Some cases with milder mutations have required liver transplantation, with its 
attendant complications, and may subsequently develop myopathy (97, 108). Over the preceding 5 years, we 
have developed an accurate method for assay of tissue-specific mitochondrial DNA content using quantitative 
real-time polymerase chain reaction (qPCR) that has led to accurate retrospective modeling and prospective 
diagnosis of patients with hepatic mtDNA depletion (55, 110-116). This is accepted as the clinical standard for 
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diagnosis of mtDNA depletion (54). The development of a robust diagnosis for MDS and the detailed 
characterization of DGUOK deficiency, in particular, suggested to us that an animal model of DGUOK 
deficiency would be of great value in developing and evaluating the potential of new diagnostic and 
pathophysiologic techniques for MD. 
 In the present work, we aim to introduce EPR of tissue samples at cryogenic temperatures as a 
mechanistic tool for MD. We have developed a rat model of DGUOK deficiency (referred to by the trivial name 
"DGUOK") that exhibits characteristic biomarkers, and we have applied standard biochemical and pathological 
tests along with EPR. The goals of this work are to characterize the DGUOK rat in terms of mitochondrial 
dysfunction and pathological outcome, and to evaluate EPR as a new and additional technique in an integrated 
characterization of MD. 
 
Materials and Methods. 
The DGUOK rat model of DGUOK deficiency. Previously described zinc-finger nuclease (ZFN) 
technology was employed (117, 118). A preferred binding/cutting site of 
GTCGGTTCCTTCTGCgtagacTCCGAGCGTCTTTCCG was identified from a clinically relevant transcript of 
DGUOK and the appropriate ZFN was obtained from Sigma Aldrich (CompoZr Custom ZFN Service). This was 
injected into the pronucleus of a fertilized one-cell embryo. These microinjected embryos were then implanted 
into a “pseudo-pregnant” recipient female rat. This resulted in the generation of four characterized DGUOK rat 
knockout lines named SSdguokM1 SSdguokM2 SSdguokM3and SSdguokM4. Because of the rare potential for an off-target 
effect, where ZFNs cause double-strand breaks and mutations at undesired loci, we backcrossed and bred 
homozygote animals from these two lines (117). The “M1” line has a 31 base pair deletion after amino acid six 
leading to a premature stop codon, i.e., a polypeptide with 34 amino acids (the first 6 from the original protein 
sequence and 28 from the missense). Similarly, the “M2” line has a 37 base pair amino acid deletion after 
amino acid six. This frame-shift mutation would lead to a 42 amino acid polypeptide with only the first 6 amino 
acids consistent with the original protein sequence. 
The M3 line had a net 57bp frameshift deletion in exon 1 including the initiation codon which is predicted 
to lead to the use of an alternate start codon in exon 1 with a 5’ truncated protein devoid of the mitochondrial 
targeting sequence. The M4 line had an in-frame deletion of 9 nucleotides in the targeting sequence. This 
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strain does not have hepatic mtDNA depletion and, because of the adequacy of the first two models, was not 
further characterized.  
The generation of the animal model and all subsequent animal experiments were performed under 
approved Animal Use Application by the Institutional Animal Care and Use Committee (IACUC) of the Medical 
College of Wisonsin (protocols 2214 and 1764, respectively). 
 mtDNA assay. Real time analysis was performed as previously published and validated in humans (55, 
97, 112) using rat specific primers. DNA was extracted using Qiagen Blood Core Kit #158389 and quantified 
using the Quant-iT PicoGreen double stranded DNA kit (Invitrogen) and a Varioskan plate reader (Thermo 
Fisher) in 96 well format. DNA is diluted to a concentration falling with in efficiency range of the assay 0.125-4 
ng/l. qPCR was carried out on 10 l samples, each containing between 0.35 and 12 ng of extracted DNA, 5 
pmol of each forward and reverse primer, and 5 l iTAQ SYBR Green Supermix with ROX (BioRad). The 
mitochondrial genome-targeted rat-specific primers used were tRNALeu F: GGTTATTAGGGTGGCAGAGC 
and tRNALeu R:GGAAGGCCATGGCAATTAAG. Nuclear primers, targeted to the ActB coding region, were 
ActB F:TACCACTGGCATTGTGATGG and ActB R: ACGCTCGGTCAGGATCTTC. The Basic Local Alignment 
Search Tool (National Center for Biotechnology Information) was used to show that primers hybridized to 
unique sequences in Rattus norvegicus. The real-time qPCR cycling conditions were (i) 50°C for 2 min, (ii) 
95°C for 10 min, (iii) 45 cycles of 15 seconds at 95°C, and (iv) a combined 62°C anneal/extension for 30 
seconds. Upon completion of 45 cycles, a pre-programmed dissociation step was carried out by one cycle of 
95°C for 15 seconds, 50°C for 15 seconds and 95°C for 15 seconds. Real-time fluorescence was measured 
and analyzed on a 7900HT Fast Real-Time PCR system (Applied Biosystems, Foster City, CA) using SDS 
V2.3 software. All samples were assayed in triplicate. The relative mtDNA copy number was determined from 
the threshold difference between the averages of each set of triplicate reactions.  
 Histology. A portion of each heart, lung, liver, spleen, and kidney from 4 wild-type SS rats and 5 
SSdguokM2DGUOK rats at 11 months of age was fixed in formalin for histological analysis. Fixed tissue was 
paraffin-embedded, sectioned, and stained with hematoxylin and eosin (H&E) using standard techniques. To 
evaluate possible liver fibrosis, sections of liver were also stained using Masson trichrome stain using standard 
techniques. For evaluation of muscle pathology, a quadriceps muscle from each animal was frozen in 
isopentane at -78.5 C, and 8 m cryosections were stained for H&E, Gomori trichrome, reduced nicotinamide 
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adenine dinucleotide (NADH), cytochrome oxidase (COX), and succinate dehydrogenase (SDH) using 
standard techniques.   
 Protein immunoblot (western blot). Protein homogenates prepared from the quadriceps muscle were 
evaluated for mitochondrial electron transport chain complex expression using standard western blot 
techniques (119). Transferred proteins were probed with a MitoProfile Total OXPHOS Blue Native WB 
Antibody Cocktail (MitoSciences #MS603, Abcam, Cambridge, MA), which includes antibodies against 
mitochondrial respiratory chain complexes I-V, and visualized using enhanced chemiluminescence. 
Quantification was performed using ImageJ version 1.44p and statistics were evaluated using Student’s t-test. 
 Electron transport chain activity assay. Electron transport chain activity assays were carried out on 
frozen rat muscle and liver (n = 6 for controls and n = 5 for DGUOK rats) according to protocols previously 
described in detail (120, 121) with the modification that the linear initial velocity in the first minute was 
determined for Complex III, instead of a formal rate constant, due to the lower activity compared to Complexes 
I, II and IV. The activities of Complexes I - IV were normalized for mitochondrial content by dividing by citrate 
synthase activity. The results of electron transport chain activity assays are not normally distributed but 
become so after transformation to their natural logarithms. Results are expressed as average values and the 
standard error of the mean. Significance is expressed by the non-parametric Mann-Whitney U test on the raw 
data and by Student's t-test of the logarithmically transformed data. Blue native PAGE analysis with in-gel 
activity staining was carried out as previously described (121-123). This allowed the identification of decreased 
synthesis of mitochondrial subunits (124).  
 EPR spectroscopy. Fresh tissue samples for EPR were rapidly extruded into 3 mm diameter EPR tubes 
and frozen in liquid nitrogen within 90 s of harvest (we have found that tissue can be frozen much more rapidly 
than dilute aqueous solutions and with much reduced risk of the EPR tube breaking). Samples entirely filled 
the active length of the EPR resonator. EPR spectra were recorded on a Bruker EleXsys E600 spectrometer 
equipped with a Super-X microwave bridge with integrated microwave counter, an ER4112SHQ resonant 
cavity operating at 9.38 GHz, and an Oxford Instruments ESR900 helium flow cryostat and ITC503 
temperature controller. Spectra were recorded with 10 G magnetic field modulation at 100 kHz and this 
modulation amplitude determined the spectral resolution. Microwave powers and temperatures are given in the 
figure legends. Scans of 4096 points, 8000 G field envelope and 3 min duration were averaged over 60 - 180 
Mitochondrial dysfunction and EPR abnormalities in DGUOK deficient rats  Bennett et al 
 
11 
min to provide the final spectrum. A background spectrum collected on frozen water was subtracted from rat 
tissue spectra. Experimental spectra were modeled by fitting a library of computed spectra corresponding to 
the mitochondrial respiratory chain centers and the [3Fe4S] cluster of aconitase (69), using a Levenberg-
Marquardt algorithm to minimize 2 (IGOR Pro v. 6.32A, Wavemetrics, Lake Oswego, OR). The contributions 
of each component were constrained to  0. Correlation matrices indicated strong interdependencies 
(correlation coefficients ~ 0.7) of contributions from the pairs of signals (i) Complex II S3 3Fe4S and aconitase 
3Fe4S, and (ii) Complex I N1b and N2 FeS clusters. N1b and N2 could not be deconvoluted and only the 
overall contribution from N1b + N2 is given, whereas S3 and aconitase were deconvoluted by the use of two 
temperatures (69). Computed spectra of the individual components were calculated with XSophe (Bruker 
Biospin; (125, 126)) using spin Hamiltonian parameters from the literature (69-79), and computed spectra were 
normalized for the intensity of ".dH (i.e. the first integral of the EPR absorption, or so-called "double-




 Recapitulation of mtDNA depletion in DGUOK rat. To evaluate the phenotype, three M2, four M1 and 
six SS 8-week-old females were sacrificed and tissue harvested. DNA was extracted and subject to qPCR 
evaluation using validated rat-specific primers, but otherwise as previously described (112). This method 
demonstrates an approximately 90% reduction in hepatic mtDNA content (Figure 1). This reduction is similar 
to the 80–90% reduction in hepatic mtDNA seen in humans with this disorder (112). Similarly, a 60–80% 
reduction in splenic DNA content was observed (100). The situation was less clear in muscle; while M1 rats 
exhibited about 60 % depletion in mtDNA, the mtDNA level in the M2 rat was indistinguishable from that in 
wild-type. Consequently mtDNA content was assessed in sections of the same tissue that was used for 
Histology, ETC and EPR assays. This demonstrates no significant difference in mtDNA content in skeletal 
muscle, regardless of predominant oxidative fiber type (Table S1).   
 Pathology of the DGUOK rat. A pathological analysis was performed on 4 wild-type and 5 DGUOK rats 
at approximately 11 months of age, including the histological evaluation of heart, lung, liver, spleen, kidney, 
and muscle.  H&E-stained sections of heart, lung, liver, spleen, and kidney revealed no apparent differences in 
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the organ histology when comparing wild-type and DGUOK rats.  Liver fibrosis was further evaluated using 
Masson trichrome staining, which also showed no evident differences between wild-type and DGUOK livers. In 
contrast, there were marked differences on oxidative enzyme staining when comparing the quadriceps 
muscles of wild-type and DGUOK rats (Figure 2).  While pathological differences were not apparent on H&E 
staining, there were numerous fibers that showed negative staining on both cytochrome oxidase (COX) and 
succinate dehydrogenase (SDH) stains (Figure 2).  Large numbers (up to 20-30% of fibers) of these COX 
negative/SDH negative fibers were seen in all DGUOK rats, whereas they were essentially absent in all of the 
wild-type rat muscles examined.     
 Expression of respiratory chain complexes. Mitochondrial protein expression was found to be altered in 
quadriceps muscle of the 11 month old DGUOK rat (Figure 3). Specifically, the data indicated that Complex I 
was significantly under-expressed (54 % of wild-type; p = 0.05) and suggested that Complex III was also under 
expressed (47 % of wild-type; p = 0.12). The expression levels of Complexes II, IV & V were unchanged in 
DGUOK rat muscle. Varying, though generally low, amounts of an unidentified immunoreactive protein with Mr 
 30 kDa were also observed.  
 Electron chain transport assays. Significantly lower activities for Complexes I, III and IV were observed 
in DGUOK rat liver, corresponding to about 20 %, 7 % and 13 % of wild-type activity, respectively, whereas 
Complex II activities were statistically indistinguishable (Figure 4, Table 1). In DGUOK muscle, the activities of 
Complexes I and III were only 9 % and 20 % of wild-type, respectively, whereas Complex II and IV activities 
were essentially indistinguishable.     
 EPR spectroscopy. The EPR spectra at 12 K of liver, quadriceps muscle and heart from wild-type and 
DGUOK rats are shown in Figure 5. The signals are complex but some features are immediately identifiable 
and are labeled a - k in Figure 5. Feature a at g' ~ 6 is due to high-spin ferriheme; b at g' ~ 4 is due largely to 
Fe(III) in transferrin; a complex pattern extending upfield from c is due to Mn(II), which is prominent in liver but 
much less so in quadriceps muscle and not detectable in heart, and overlaps the signals from the respiratory 
chain iron sulfur clusters; the prominent feature at d is the so-called "g = 2.01" signal and is due to overlapping 
signals from the oxidized 3Fe4S clusters of Complex II and oxidatively-damaged aconitase; the signal at e, the 
so-called "g = 1.94" signal, is due to overlapping g2 resonances from reduced 2Fe2S and 4Fe4S clusters, 
primarily those from Complex I; the signals at f are the g3 resonances from Complex I N4 4Fe4S (lower field) 
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and Complex I N3 2Fe2S (higher field) and are overlaid on the highest field mI = 
5/2 resonance of the mS = 
1/2 
manifold of S = 5/2 Mn(II) (the latter is not clear in trace A but much more pronounced in trace B); the 
resonances labeled g are gx and gy of the rhombic high-spin ferriheme of catalase (88); the resonances around 
h are due to low-spin ferriheme; feature i is the g1 (gx) resonance of low-spin heme a of Complex IV; and k 
indicates the g1 (gx; lower field) and g3 (gz; higher field) resonances from the Rieske 2Fe2S cluster of Complex 
II. The broad EPR absorption in the liver spectra from about 2000 G is largely due to rapid-passage of the 
Mn(II) leading to an absorption-like signal that includes components from the mS = 
3/2 and mS = 
5/2 manifolds 
(127), along with some contribution from CuA of Complex IV. 
 Visual inspection of the spectra provides some limited information. Mn(II) is clearly elevated in DGUOK 
liver whereas the reduced Complex I FeS signals (e, f) are diminished. In DGUOK quadriceps muscle, the 
Complex I FeS signals and the Complex III Rieske signals are markedly diminished compared to wild-type. In 
both muscle and liver, the g = 2.01 signal (d) due to Complex II S3 and/or aconitase appears elevated in 
DGUOK compared to wild-type. To further investigate this phenomenon, spectra were recorded at 40 K 
(Figure 6) where the faster-relaxing S3 signal intensity is lowered relative to the more slowly relaxing 
aconitase signal. In liver, the difference in intensity of the g = 2.01 signal persists and we assign this as being 
due to a 25 % increase in the aconitase signal in DGUOK over wild-type. In quadriceps muscle at 40 K, the 
DGUOK signal is now smaller than the wild-type signal, indicating that the difference at 12 K is due to elevated 
amounts of oxidized Complex III S3 3Fe4S. Clear signals due to g1 (gx) of heme a of Complex IV were only 
observed in heart. The signals in liver and quadriceps were much broader and suggestive of a distribution of g-
values; this resonance position of this signal was found to be very sensitive to mutations in bacterial 
cytochrome c oxidase (128) and the apparent distribution of g1 values may reflect multiple environments in liver 
mitochondria. In liver, the signal from transferrin was elevated and that from catalase was depressed. 
Interestingly, no significant differences at all were observed between the EPR spectra of heart from wild-type 
and DGUOK rats. 
 For quantitative information we turned to computer simulation of the spectra. Figure 7 shows the g ~ 2 
region of the experimental spectra for liver (A, B), quadriceps muscle (E, F) and heart (I, J) from DGUOK and 
wild-type rats. In each case, fits to the library of computed spectra were generated. As we are particularly 
interested in the differences between wild-type and DGUOK, difference spectra (DGUOK minus wild-type) of 
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the experimental data (C, G and K for liver, muscle and heart, respectively) and the computed fits (D and H for 
liver and muscle; no significant difference was observed between the fits to wild-type and DGUOK heart) are 
presented. The experimental and computed difference spectra match very well and details of the fits are given 
in Table 2/Table S2. From the fit parameters, and using the dual temperature study to resolve the S3 and 
aconitase 3Fe4S contributions, we calculated the fractional difference between the intensities of each of the 
components in the DGUOK and wild-type tissues, and the significant results are summarized in Figure 8. 
 
Discussion. 
 The aims of this work are to describe the DGUOK rat mitochondrial phenotype and evaluate it as a 
model for mitochondrial disease, and to apply EPR spectroscopy of tissue to enable an understanding of what 
happens at the electron level in tissue with mtDNA depletion. The DGUOK rat has a complex and tissue-
dependent mitochondrial phenotype. The DGUOK liver exhibited markedly lower mtDNA copy number, ~ 10 % 
of wild-type. However, EPR showed that Complex I FeS clusters were present at least 50 % as much as in 
wild-type, and signals from S1, S2, S3 and the Rieske FeS clusters indicated that Complexes II and III are 
expressed at the same level as in wild-type. The observation that the four EPR-detectable FeS cluster signals 
are depleted by the same amounts, despite very different redox potentials, and that signal intensities from both 
the S1-S2 pair and the Rieske cluster are indistinguishable from wild-type suggests that (i) the lowered 
Complex I signals are due to depressed expression or Fe incorporation, rather than an elevated redox potential, 
and (ii) the depleted Complex I complement therefore provides sufficient electrons to load the electron transfer 
chain. The aconitase 3Fe4S signal, a characteristic marker for oxidative stress (82), was elevated in DGUOK 
liver. Also, Mn(II), which is present at high levels in wild-type liver and is proposed to be additionally generated 
in response to oxidative stress (127), was doubled compared to wild-type. The activities of Complexes I, III and 
IV in DGUOK liver were very depressed compared to wild-type, and by far more that can be accounted for by 
expression levels. It is tempting to speculate that the oxidative stress identified by the aconitase and Mn(II) 
EPR signals is either a cause or consequence of the additional Complex I, II and IV dysfunction in DGUOK 
liver. The very low levels of Complexes III and IV activities explain the EPR observation that the electron 
transfer chain remains electron-rich, and the redox potential maintained close to the NADH:NAD midpoint 
potential, even though Complex I activity is also significantly depressed. The elevation of the EPR signal from 
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transferrin may indicate some hemorrhaging, and the depression of the catalase signal also suggests some 
disease or damage to the liver (129). 
 The mitochondrial phenotype in DGUOK quadriceps muscle is also complex. Consistent with muscle 
evaluated in humans with severe disease, protein expression levels for Complexes I and III were also ~ 50 % 
of wild-type, whereas Complexes II, IV and V were expressed at wild-type (108). However, in contrast to 
humans with severe disease, the mtDNA copy numbers for wild-type and M2 DGUOK were similar across all 
muscle groups [table S1]. This lack of difference in the muscle types may reflect variability in sampling, the 
milder phenotype in the rats or an underlying correction in muscle tissue for example by de novo purine 
synthesis or alternate salvage pathways. This data underscores the limited sensitivity of qPCR previously 
described in human muscle (112) and emphasizes the need to consider evaluation of liver specifically for 
depletion in this disease. 
Consistent with protein expression levels, EPR of DGUOK quadriceps muscle indicated that Complex I 
is present at  35 % of the wild-type level and Complex III at about 50 %. The EPR data for Complex II are 
revealing. The S3 cluster signal was twice as intense as in wild-type, yet the S1 and S2 clusters were 
diminished by a factor of two. This could indicate a catastrophic inability to correctly assemble Complex II or 
incorporate S1 and S2 but this would be expected to essentially abolish activity, and the elevation of S3 would 
require a doubling of Complex II expression. Neither phenomenon was observed. More likely, the changes in 
S1, S2 and S3 reflect a Complex II that experiences a significantly more oxidizing redox potential than in wild-
type mitochondria. This hypothesis is strongly supported by the very low Complex I electron transferring 
activity compared to the downstream activities of Complexes II, III and IV. Therefore, Complex II is drained of 
electrons and produces the EPR signature observed in DGUOK quadriceps muscle. This scenario also 
explains the lack of markers for oxidative stress in the EPR signature of DGUOK muscle. In the absence of 
Complex I activity, very few electrons enter the respiratory chain to begin with. Furthermore, the downstream 
components are in a more oxidized state and thus are primed to receive any electrons that do enter the 
respiratory chain, essentially acting as antioxidants. So, while Complex III dysfunction results in electron build-
up and oxidative stress in DGUOK liver, the lack of activity of Complex I and downstream oxidation of 
Complexes II - IV in muscle does not result in oxidative stress even though Complex III activity is as depressed 
in muscle as it is in liver. The only EPR marker observed for Complex IV in this study, the heme a signal, was 
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very weak and broad in muscle and was not significant in the fits. Nevertheless, visual examination suggests a 
comparable signal in wild-type and DGUOK, consistent with the significant Complex IV activity. What remains 
unclear is the reason(s) behind the low activities of Complexes I and III. Native PAGE provides no evidence for 
subunit depletion, and EPR does not indicate oxidative stress. 
 In contrast to liver and quadriceps muscle, the heart in the DGUOK rat appears entirely unaffected. The 
mtDNA copy numbers are normal and the EPR signals of wild-type and DGUOK heart are indistinguishable 
themselves and very similar to wild-type quadriceps muscle. Large EPR signals from Complex I N3 and N4, a 
large signal from Complex III Rieske 2Fe2S, a high ratio of the g = 1.94 and g = 2.01 signals, and a weak 
signal from Complex IV heme a all indicate a very reducing environment that is consistent with an active 
Complex I and a fully functioning respiratory chain that does not produce oxidative stress. 
 EPR is a unique tool in that it can interrogate the status of the mitochondrion at the time of freezing, in 
unprocessed viable biological samples. First, it is clear that in both liver and quadriceps muscle, EPR identified 
mitochondrial dysfunction in the DGUOK rat. Second, some mechanistic information on the DGUOK rat was 
obtained. In liver, the EPR results indicated that the reduced electron transfer chain activity of Complexes I is 
in part due to reduced expression but that the very low activity of Complex, III is not a consequence of reduced 
expression or Fe incorporation as FeS clusters. The retention of the Complex III Rieske 2Fe2S EPR signal in 
DGUOK liver indicates that Complex III is present at wild-type levels, incorporates the Rieske cluster, and 
electrons can progress through the respiratory chain at least as far as the Rieske cluster. The reason for 
Complex III inactivity remains unknown but appears to be downstream of the Rieske cluster. Oxidative stress 
may be important, and two independent markers for oxidative stress were identified, elevated aconitase 3Fe4S 
and Mn(II); two markers for liver damage were also identified, depressed catalase and elevated transferrin. In 
quadriceps muscle, EPR provides complementary information to the activity assays. The lack of Complex I 
activity and the EPR identification of oxidation of the three Complex II FeS clusters provides a rationale for the 
lack of any EPR markers for oxidative stress in muscle. A knowledge of whether oxidative stress is a 
consequence of mitochondrial disease, and in which tissues and why, is an important piece of information that 
may inform therapy choices.  
 
Conclusions. 
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The DGUOK rat capitulates major biochemical features observed in humans with DGUOK deficiency, 
specifically significantly reduced mtDNA content, reduced mitochondrial complex I, III and IV protein content 
and enzymatic activity in frozen liver.  EPR assessment of flash-frozen tissues has demonstrated dramatic 
differences in the mitochondrial electron transport chain status in situ compared with wild-type animals. The 
reproducibility and magnitude of these differences is encouraging given the relatively mild pathologic 
differences seen in the animals. It suggests that EPR may be able to reliably distinguish individuals with 
mitochondrial disease from distinct etiologies of muscle or liver disease in humans.   
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1000 x Wild-type 
activity  citrate 
synthase activity 
 
1000 x DGUOK 
activity  citrate 
synthase activity 
Mann-Whitney 




LIVER     
Complex I 230.08 ± 18.81 47.64 ± 9.53 0.008 0.002 
Complex II 991.9 ± 95.3  1291.6 ± 258.3 0.522 0.250 
Complex III 14.35 ± 0.80 1.02 ± 0.20 0.008 0.001 
Complex II - III 430.1 ± 32.6 129.3 ± 25.9 0.029 0.012 
Complex IV 137.54 ± 11.69 17.70 ± 3.54 0.014 0.002 
     
MUSCLE     
Complex I 108.1 ± 8.25 9.73 ± 4.25 0.008 0.015 
Complex II 278.1 ± 16.42 215.8 ± 18.41 0.522 0.093 
Complex III 3.43 ± 0.48 0.70 ± 0.18 0.036 0.025 
Complex II -III 263.7 ± 28.53 157.6 ± 15.36 1.00 0.070 
Complex IV 38.63 ± 5.60 53.93 ± 8.76 0.412 0.434 
 
Table 1. Results of electron transport chain assays of Complexes I - IV from muscle and liver from wild-type and 
DGUOK rats. 
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CuA 47 ± 13 44 ± 15 
[NS]c 
9 ± 1 13 ± 1 
[+45] 
NDd 
Heme a 200 ± 50 100 ± 60 
[-50] 
ND ND 200 ± 30 
High-spin heme 116 ± 7 71 ± 9 
[-39] 
44 ± 1 31 ± 1 
[-30] 
183  3 
N1b + N2 26 ± 5 16 ± 5 
[-39] 
28.2 ± 0.2 7.4 ± 0.5 
[-74] 
111  1 
FeS N3 17 ± 8 8 ± 5 
[-53] 
16 ± 1 5.5 ± 0.7 
[-61] 
38  4 
FeS N4 41 ± 8 20 ± 6 
[-51] 
33 ± 1 14 ± 1 
[-59] 
108  4 
All Complex I FeS 84 ± 12 44 ± 9 
[-49] 
77 ± 1 26 ± 1 
[-66] 
257  6 
S3 + Acn 10.8 ± 1.6 15 ± 2 
[+37] 
1.3 ± 0.1 3.8 ± 0.1 
[+192] 
17  1 
FeS S1 27 ± 10 29 ± 13 
[NS] 
15 ± 1 8 ± 1 16 ± 5 
FeS S2 ND ND ND ND 60 ± 5 
S1 + S2 27 ± 10 29 ± 13 
[NS] 
15 ± 1 8 ± 1 
[-48] 
76 ± 7 
Rieske FeS 99 ± 11 98 ± 12 
[NS] 
37 ± 1 18 ± 1 
[-51] 
238 ± 5 
Mn(II) 295 ± 27 588 ± 32 
[+99] 




Table 2. Fitting parameters for the EPR signals from spectra of liver and muscle tissue from wild-type and DGUOK rats. 
The absolute intensities of each species (or group of species) are shown for wild-type and DGUOK, along with the 
percentage differences between DGUOK and wild-type intensities in brackets. 
 
Footnotes. (a) Calculated as {[(DGUOK signal) - (wild-type signal)]  (wild-type signal)}  100. (b) Wild-type and 
































Figure 1. Absolute mtDNA content in DGUOK rats. The mtDNA copy numbers for eight week old M1 and M2 
DGUOK knockout rats compared with wild-type (SS) rats. The error bars indicate standard deviations for n = 6 (SS), n = 
4 (M1) and n = 3 (M2). 
 








Figure 2: Skeletal muscle pathology in 11 month old WT and DGUOK rats.  Quadriceps muscles from DGUOK rats 
display little differences on H&E staining in comparison to WT littermates.  In contrast, staining for COX and SDH 
reveals numerous fibers in DGUOK rat muscle that are negative for both COX and SDH, whereas no such fibers were 
evident in WT rat muscle.  The bar at the bottom, right corresponds to 200 m. 
  






































Figure 3. Respiratory chain complex expression in DGUOK rat muscle. Western blots of mitochondrial electron 
transport chain complexes I-V and GAPDH from stripped membranes of quadriceps muscle from 11 month old wild-type 
and DGUOK rats are shown in the top panel. The results of quantitation of the respiratory chain complex bands are shown 
below, normalized for GAPDH expression. The error bars indicate standard errors for n = 4.  
  







































 Figure 4. Electron transport chain functional assays of Complexes I - IV. The functional activities of 
Complexes I - IV from liver and quadriceps muscle of DGUOK rat are shown, normalized for mitochondrial content (as 
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Figure 5. 12 K EPR spectra from wild-type and DGUOK rat tissue. The spectra are from samples of A, wild-type rat 
liver; B, DGUOK rat liver; C, wild-type rat quadriceps muscle; D, DGUOK rat quadriceps muscle; E, wild-type rat heart; 
and F, DGUOK rat heart. In each case, the sample completely filled the part of the EPR tube that occupied the active 
region of the resonator. A & B shown x 1, C & D are shown x 2, and E & F shown x 0.5. Spectra were recorded at 12 K, 
2.5 mW power. The lower-case labels identify specific signals in the spectra: (a) high-spin axial ferriheme g; (b) 
transferrin non-heme Fe(III); (c) the mI = 
5
/2 line at the low-field extremity of the six-line Mn(II) hyperfine pattern; (d) 
overlapping signals from aconitase and S3 [3Fe4S] clusters; (e) overlapping g2 resonances from Complex I [2Fe2S] and 
[4Fe4S] clusters; (f) resolved g3 resonances from N4 and N3 clusters; (g) high-spin catalase gx and gy lines; (h) low-spin 
catalase resonances; (i) heme a g1; and (k) Rieske [2Fe2S] cluster g1 and g3 resonances. 
  
































Figure 6. 40 K EPR spectra from wild-type and DGUOK rat tissue. The spectra are from samples of A, wild-type rat 
liver (solid line) and DGUOK rat liver (dashed line); and B, wild-type rat quadriceps muscle (solid line) and DGUOK rat 
muscle (dashed line). Spectra were recorded at 40 K, 2.5 mW power.  
 
  








































Figure 7. Quantitative analysis of the 12 K EPR signals from wild-type and DGUOK rat tissues. Traces A, B, E, F, I 
and J show the g' ~ 2 region of the EPR spectra of A, wild-type rat liver; B, DGUOK rat liver; E, wild-type rat quadriceps 
muscle; F, DGUOK rat quadriceps muscle; I, wild-type rat heart; and J, DGUOK rat heart. Trace C is the difference 
spectrum obtained by subtraction of A from B, and is shown multiplied by a factor of two; likewise, G = 2(F - E) and K 
= 2(J - I). Trace D is a theoretical simulation of C generated by the subtraction of fits of A and B to model spectra of the 
paramagnetic species likely to be observed in the mitochondrion. Fitting parameters are presented in Table 2 (or S2). 
Similarly, trace H is a simulation of J from fits to E and F. No attempt was made to simulate K, as no significant 
differences were observed between fits to I and J. 
 
  


































Figure 8. Summary of EPR of DGUOK rat liver and muscle. A comparison of signal intensities is shown for some of 
the respiratory complex redox centers in liver and muscle from the DGUOK and wild-type rat. The standard errors were 
calculated from those of the fit parameters, presented in Table 2 (or S2). 
 
  




In contrast to liver (n=5), mtDNA content in muscle tissue from 4 Wild Type (Dahl/SS) rats compared with 4 
DGUOK M2 rats demonstrates no significant difference. 
  
 WILD TYPE RAT DGUOK M2 RAT TTEST 
SOLEUS MUSCLE 1036 710 0.72 
GASTROCNEMIUS MUSCLE 910 571 0.31 
TRICEP MUSCLE 1270 418 0.25 
DELTOID MUSCLE 1043 1043 0.81 
LIVER 1981 187 0.0002 
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A novel rat model for a well-characterized human mitochondrial disease, mitochondrial DNA depletion 
syndrome with associated deoxyguanosine kinase (DGUOK) deficiency, is described. The rat model 
recapitulates the pathologic and biochemical signatures of the human disease. The application of electron 
paramagnetic (spin) resonance (EPR) spectroscopy to the identification and characterization of respiratory 
chain abnormalities in the mitochondria from freshly frozen tissue of the mitochondrial disease model rat is 
introduced. EPR is shown to be a sensitive technique for detecting mitochondrial functional abnormality in situ 
and, here, is particularly useful in characterizing the redox state changes and oxidative stress that can result 
from depressed expression and/or diminished specific activity of the distinct respiratory chain complexes. As 
EPR requires no sample preparation or non-physiological reagents, it provides information on the status of the 
mitochondrion as it was in the functioning state. On its own, this information is of use in identifying respiratory 
chain dysfunction; in conjunction with other techniques, the information from EPR shows how the respiratory 
chain is affected at the molecular level by the dysfunction. It is proposed that EPR has a role in mechanistic 




DGUOK, redox, oxidative, stress, mtDNA depletion, pathology 
 
Graphical abstract. 










COX, cytochrome oxidase; M2, deoxyguanosine kinase-deficient rat model; DGUOK, deoxyguanosine kinase; 
EPR (ESR), electron paramagnetic (spin) resonance; FeS, iron-sulfur (cluster); H&E, hematoxylin and eosin; 
MD, mitochondrial disease; MDS, mitochondrial DNA depletion syndrome; MPV17 mitochondrial inner 
membrane protein; mtDNA, mitochondrial DNA; NADH, reduced nicotinamide adenine dinucleotide; POLG, 
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DNA polymerase γ; SDH, succinate dehydrogenase; TWINKLE, a mitochondrial DNA helicase encoded by 
chromosome 10, open reading frame 2 (also known as C10orf2) 
 
  




 Mitochondrial disease (MD) occurs where depletion of mitochondrial DNA (mtDNA) or mutations in 
mtDNA and/or nuclear DNA (nDNA) lead to altered mitochondrial function.(1-4) Altered activities of Complexes 
I – V have been identified and physiological consequences of mitochondrial respiratory chain defects include 
reduced metabolic capacity, reduced ATP synthesis, and increased oxidative and nitrosative stress.(5-15) 
Symptoms of MD are manifold and include weakness (from central nervous system, peripheral nerve, and/or 
skeletal muscle disease), pain, intolerance of some general anesthetics and anti-epileptic drugs, 
gastrointestinal disorders, ophthalmoplegia and/or visual failure, failure to thrive, cardiac and respiratory 
disease, liver disease, diabetes, seizures, sensorineural hearing loss, mental retardation, dementia, movement 
disorders, increased susceptibility to infection, and pregnancy loss.(1, 2, 16-38) Establishing diagnoses and 
understanding the pathophysiology of mitochondrial disease (MD) has proven extremely challenging because 
of the extraordinary range of clinical symptoms and testing abnormalities (39). MD is often suspected in early 
childhood from clinical differential diagnosis of patients with diseases involving the brain, muscle, or liver. 
Traditional methods for diagnosing MD include clinical presentation, family history, pathology, metabolic 
profiling, enzyme activity levels, electrophysiology, magnetic resonance imaging (MRI) of brain and magnetic 
resonance spectroscopy (MRS) of metabolites, and mtDNA analysis (3, 7, 31, 40-53). Additional indicators 
include observation of mitochondrial proliferation, abnormalities on muscle histology (e.g., ragged red fibers or 
succinate dehydrogenase-positive fibers) (41, 54), and abnormalities in electron microscopy (46, 55). However, 
muscle histology may be normal despite the presence of biochemical abnormalities in the tissue. The 
determination of whether MD is present in a given patient can be extremely complex, given that (i) 
mitochondrial function can be secondarily affected due to the disease processes in non-mitochondrial diseases, 
(ii) there can be extensive variability in the distribution of abnormal mitochondria within an individual patient, 
allowing a “false negative” testing profile to occur when tissues with mitochondrial abnormalities are not tested, 
and (iii) there are no uniform, definitive pathological abnormalities that distinguish all MD patients from patients 
with other disorders. Diagnosis may ultimately rely on the application of diagnostic algorithms to predict the 
likelihood of MD  (56, 57) but MD is currently an under-diagnosed disease (4, 58-64). 
 Mechanistic information on MD has largely arisen from mitochondrial electron transport chain 
component activity assays on the components, isolated from their native matrix from fresh or frozen tissue, or 
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from cultured cells. These assays are, like most clinical biochemical assays, performed under non-physiologic 
basal conditions and with very different substrate concentrations than are seen in-vivo. Complex interactions 
between the substrates of these assays and other cellular components can lead to erroneous results (65) 
though these problems can, in principle be, overcome with careful isolation of proteins or in-gel assays. Assays 
of activities outside of the intact mitochondrial environment cannot identify defects in mitochondrial membrane 
potential or coupling. In clinical practice, it has been found that the methodological variations, limitations and 
difficulties associated with the use of respiratory chain functional assays as a diagnostic method for MD has 
led to massive inter-laboratory variability in results (66). In alternative approaches, substrates are added to 
whole cells or isolated mitochondrial preparations, and either oxygen consumption or ATP generation is 
measured [reviewed in (67)]. While recognized as the current standard for mitochondrial testing there are, 
again, significant limitations. Most apparent is the requirement for viable functioning mitochondria, requiring cell 
preparation or mitochondrial isolation and testing to be carried out temporally, and therefore geographically, 
proximate to the biopsy. The process of isolating mitochondria from native tissue risks damage and places the 
organelle outside of a truly physiologic condition. Conversely, whole cell assays require permeabilization of the 
cell to the substrates and transport to the mitochondria. The potentially limited ability to get reagents to the site 
of action can lead to a loss of sensitivity and specificity. In all of the currently employed assays, the 
mitochondrial function is not assessed in its native-organ context in the human and the need persists for an 
assay that measures the functional ability of mitochondria in an intact tissue preserved in a state as close as 
possible to that in situ.  
 Electron paramagnetic (spin) resonance (EPR, ESR) is a technique that can provide unique insight into 
mitochondrial status. EPR detects and characterizes free radicals and many transition metal ions and clusters 
in biological systems by measuring the magnetic field dependence of the absorption of microwave radiation at 
a given frequency by the unpaired electrons residing in these species (68). The mitochondrial respiratory chain 
Complexes I - IV are particularly rich in transition metal-containing redox centers, with a complement of 21 
centers that include heme iron, copper, and [2Fe2S], [3Fe4S] and [4Fe4S] iron sulfur (FeS) clusters. Up to 18 
of these adopt EPR-detectable paramagnetic states in native mitochondria and are readily observed at 
temperatures close to liquid helium (10 - 40 K) (69). The spin-Hamiltonian parameters, midpoint potentials and 
relaxation behavior of these centers have been reasonably well characterized (69-87), along with some other 
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tissue-specific signals from transferrin, ceruloplasmin, and catalase (88-90). Specific applications of EPR to 
mitochondria have included detection of an irreversible deficiency in Complex I FeS clusters in iron-deficient 
rats (91), heme-nitrosyl in substantia nigra of Parkinson's diseased brain (92), chromium-dependent inhibition 
of Complexes I & II and aconitase (93), cardio- and neuro-protection against doxorubicin (80), prophylaxis 
against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in a Parkinson's mouse model (82), the differential 
sensitivity of aconitase  and FeS clusters from Complexes I & III to oxidative and nitrosative stress in heart (94), 
and the sensitivity of Complex III FeS clusters in aging heart to ischemia (95). However, despite these 
successes in mechanistic studies, the authors are unaware of any direct application of EPR for functional 
pathophysiologic studies in humans or whole animal models with primary mitochondrial disease; the closest 
analog is a study in which a comparison of EPR signals from muscle biopsies of sepsis patients indicated 
significant depletion of Complex I FeS signals in those who died compared to survivors (86, 96). 
 One group of MD that has been recently well-characterized and suggests itself as a promising model 
for evaluation of new pathophysiologic methodologies is the mitochondrial DNA (mtDNA) depletion syndromes 
(MDS). MDS comprises a genetically and clinically heterogeneous group of autosomal recessive diseases 
characterized by a reduction in tissue-specific mtDNA copy number. This reduction is a result of molecular 
defects in either the genes responsible for mtDNA biogenesis, or those required for the maintenance of 
deoxynucleotide pools or mtDNA integrity (97-99). The loss of mtDNA can lead to a variety of clinical 
presentations that are dependent on the gene involved and the nature of the mutation. Depletion of mtDNA is 
the most common cause of multi-systemic oxidative phosphorylation defects (100), with deoxyguanosine 
kinase (DGUOK) deficiency being the most frequent cause. Death commonly results from liver failure (26, 97, 
101, 102), which may occur in the context of natural disease progression, exposure to sodium valproate (103-
105) or complications of viral infections such as influenza (55, 106). Less severe attenuation of DGUOK 
function may result in a susceptibility to isolated liver failure (97, 107, 108) or a myopathic presentation of 
DGUOK deficiency (109). Some cases with milder mutations have required liver transplantation, with its 
attendant complications, and may subsequently develop myopathy (97, 108). Over the preceding 5 years, we 
have developed an accurate method for assay of tissue-specific mitochondrial DNA content using quantitative 
real-time polymerase chain reaction (qPCR) that has led to accurate retrospective modeling and prospective 
diagnosis of patients with hepatic mtDNA depletion (55, 110-116). This is accepted as the clinical standard for 
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diagnosis of mtDNA depletion (54). The development of a robust diagnosis for MDS and the detailed 
characterization of DGUOK deficiency, in particular, suggested to us that an animal model of DGUOK 
deficiency would be of great value in developing and evaluating the potential of new diagnostic and 
pathophysiologic techniques for MD. 
 In the present work, we aim to introduce EPR of tissue samples at cryogenic temperatures as a 
mechanistic tool for MD. We have developed a rat model of DGUOK deficiency (referred to by the trivial name 
"DGUOK") that exhibits characteristic biomarkers, and we have applied standard biochemical and pathological 
tests along with EPR. The goals of this work are to characterize the DGUOK rat in terms of mitochondrial 
dysfunction and pathological outcome, and to evaluate EPR as a new and additional technique in an integrated 
characterization of MD. 
 
Materials and Methods. 
The DGUOK rat model of DGUOK deficiency. Previously described zinc-finger nuclease (ZFN) 
technology was employed (117, 118). A preferred binding/cutting site of 
GTCGGTTCCTTCTGCgtagacTCCGAGCGTCTTTCCG was identified from a clinically relevant transcript of 
DGUOK and the appropriate ZFN was obtained from Sigma Aldrich (CompoZr Custom ZFN Service). This was 
injected into the pronucleus of a fertilized one-cell embryo. These microinjected embryos were then implanted 
into a “pseudo-pregnant” recipient female rat. This resulted in the generation of four characterized DGUOK rat 
knockout lines named SSdguokM1 SSdguokM2 SSdguokM3and SSdguokM4. Because of the rare potential for an off-target 
effect, where ZFNs cause double-strand breaks and mutations at undesired loci, we backcrossed and bred 
homozygote animals from these two lines (117). The “M1” line has a 31 base pair deletion after amino acid six 
leading to a premature stop codon, i.e., a polypeptide with 34 amino acids (the first 6 from the original protein 
sequence and 28 from the missense). Similarly, the “M2” line has a 37 base pair amino acid deletion after 
amino acid six. This frame-shift mutation would lead to a 42 amino acid polypeptide with only the first 6 amino 
acids consistent with the original protein sequence. 
The M3 line had a net 57bp frameshift deletion in exon 1 including the initiation codon which is predicted 
to lead to the use of an alternate start codon in exon 1 with a 5’ truncated protein devoid of the mitochondrial 
targeting sequence. The M4 line had an in-frame deletion of 9 nucleotides in the targeting sequence. This 
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strain does not have hepatic mtDNA depletion and, because of the adequacy of the first two models, was not 
further characterized.  
The generation of the animal model and all subsequent animal experiments were performed under 
approved Animal Use Application by the Institutional Animal Care and Use Committee (IACUC) of the Medical 
College of Wisonsin (protocols 2214 and 1764, respectively). 
 mtDNA assay. Real time analysis was performed as previously published and validated in humans (55, 
97, 112) using rat specific primers. DNA was extracted using Qiagen Blood Core Kit #158389 and quantified 
using the Quant-iT PicoGreen double stranded DNA kit (Invitrogen) and a Varioskan plate reader (Thermo 
Fisher) in 96 well format. DNA is diluted to a concentration falling with in efficiency range of the assay 0.125-4 
ng/l. qPCR was carried out on 10 l samples, each containing between 0.35 and 12 ng of extracted DNA, 5 
pmol of each forward and reverse primer, and 5 l iTAQ SYBR Green Supermix with ROX (BioRad). The 
mitochondrial genome-targeted rat-specific primers used were tRNALeu F: GGTTATTAGGGTGGCAGAGC 
and tRNALeu R:GGAAGGCCATGGCAATTAAG. Nuclear primers, targeted to the ActB coding region, were 
ActB F:TACCACTGGCATTGTGATGG and ActB R: ACGCTCGGTCAGGATCTTC. The Basic Local Alignment 
Search Tool (National Center for Biotechnology Information) was used to show that primers hybridized to 
unique sequences in Rattus norvegicus. The real-time qPCR cycling conditions were (i) 50°C for 2 min, (ii) 
95°C for 10 min, (iii) 45 cycles of 15 seconds at 95°C, and (iv) a combined 62°C anneal/extension for 30 
seconds. Upon completion of 45 cycles, a pre-programmed dissociation step was carried out by one cycle of 
95°C for 15 seconds, 50°C for 15 seconds and 95°C for 15 seconds. Real-time fluorescence was measured 
and analyzed on a 7900HT Fast Real-Time PCR system (Applied Biosystems, Foster City, CA) using SDS 
V2.3 software. All samples were assayed in triplicate. The relative mtDNA copy number was determined from 
the threshold difference between the averages of each set of triplicate reactions.  
 Histology. A portion of each heart, lung, liver, spleen, and kidney from 4 wild-type SS rats and 5 
SSdguokM2DGUOK rats at 11 months of age was fixed in formalin for histological analysis. Fixed tissue was 
paraffin-embedded, sectioned, and stained with hematoxylin and eosin (H&E) using standard techniques. To 
evaluate possible liver fibrosis, sections of liver were also stained using Masson trichrome stain using standard 
techniques. For evaluation of muscle pathology, a quadriceps muscle from each animal was frozen in 
isopentane at -78.5 C, and 8 m cryosections were stained for H&E, Gomori trichrome, reduced nicotinamide 
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adenine dinucleotide (NADH), cytochrome oxidase (COX), and succinate dehydrogenase (SDH) using 
standard techniques.   
 Protein immunoblot (western blot). Protein homogenates prepared from the quadriceps muscle were 
evaluated for mitochondrial electron transport chain complex expression using standard western blot 
techniques (119). Transferred proteins were probed with a MitoProfile Total OXPHOS Blue Native WB 
Antibody Cocktail (MitoSciences #MS603, Abcam, Cambridge, MA), which includes antibodies against 
mitochondrial respiratory chain complexes I-V, and visualized using enhanced chemiluminescence. 
Quantification was performed using ImageJ version 1.44p and statistics were evaluated using Student’s t-test. 
 Electron transport chain activity assay. Electron transport chain activity assays were carried out on 
frozen rat muscle and liver (n = 6 for controls and n = 5 for DGUOK rats) according to protocols previously 
described in detail (120, 121) with the modification that the linear initial velocity in the first minute was 
determined for Complex III, instead of a formal rate constant, due to the lower activity compared to Complexes 
I, II and IV. The activities of Complexes I - IV were normalized for mitochondrial content by dividing by citrate 
synthase activity. The results of electron transport chain activity assays are not normally distributed but 
become so after transformation to their natural logarithms. Results are expressed as average values and the 
standard error of the mean. Significance is expressed by the non-parametric Mann-Whitney U test on the raw 
data and by Student's t-test of the logarithmically transformed data. Blue native PAGE analysis with in-gel 
activity staining was carried out as previously described (121-123). This allowed the identification of decreased 
synthesis of mitochondrial subunits (124).  
 EPR spectroscopy. Fresh tissue samples for EPR were rapidly extruded into 3 mm diameter EPR tubes 
and frozen in liquid nitrogen within 90 s of harvest (we have found that tissue can be frozen much more rapidly 
than dilute aqueous solutions and with much reduced risk of the EPR tube breaking). Samples entirely filled 
the active length of the EPR resonator. EPR spectra were recorded on a Bruker EleXsys E600 spectrometer 
equipped with a Super-X microwave bridge with integrated microwave counter, an ER4112SHQ resonant 
cavity operating at 9.38 GHz, and an Oxford Instruments ESR900 helium flow cryostat and ITC503 
temperature controller. Spectra were recorded with 10 G magnetic field modulation at 100 kHz and this 
modulation amplitude determined the spectral resolution. Microwave powers and temperatures are given in the 
figure legends. Scans of 4096 points, 8000 G field envelope and 3 min duration were averaged over 60 - 180 
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min to provide the final spectrum. A background spectrum collected on frozen water was subtracted from rat 
tissue spectra. Experimental spectra were modeled by fitting a library of computed spectra corresponding to 
the mitochondrial respiratory chain centers and the [3Fe4S] cluster of aconitase (69), using a Levenberg-
Marquardt algorithm to minimize 2 (IGOR Pro v. 6.32A, Wavemetrics, Lake Oswego, OR). The contributions 
of each component were constrained to  0. Correlation matrices indicated strong interdependencies 
(correlation coefficients ~ 0.7) of contributions from the pairs of signals (i) Complex II S3 3Fe4S and aconitase 
3Fe4S, and (ii) Complex I N1b and N2 FeS clusters. N1b and N2 could not be deconvoluted and only the 
overall contribution from N1b + N2 is given, whereas S3 and aconitase were deconvoluted by the use of two 
temperatures (69). Computed spectra of the individual components were calculated with XSophe (Bruker 
Biospin; (125, 126)) using spin Hamiltonian parameters from the literature (69-79), and computed spectra were 
normalized for the intensity of ".dH (i.e. the first integral of the EPR absorption, or so-called "double-




 Recapitulation of mtDNA depletion in DGUOK rat. To evaluate the phenotype, three M2, four M1 and 
six SS 8-week-old females were sacrificed and tissue harvested. DNA was extracted and subject to qPCR 
evaluation using validated rat-specific primers, but otherwise as previously described (112). This method 
demonstrates an approximately 90% reduction in hepatic mtDNA content (Figure 1). This reduction is similar 
to the 80–90% reduction in hepatic mtDNA seen in humans with this disorder (112). Similarly, a 60–80% 
reduction in splenic DNA content was observed (100). The situation was less clear in muscle; while M1 rats 
exhibited about 60 % depletion in mtDNA, the mtDNA level in the M2 rat was indistinguishable from that in 
wild-type. Consequently mtDNA content was assessed in sections of the same tissue that was used for 
Histology, ETC and EPR assays. This demonstrates no significant difference in mtDNA content in skeletal 
muscle, regardless of predominant oxidative fiber type (Table S1).   
 Pathology of the DGUOK rat. A pathological analysis was performed on 4 wild-type and 5 DGUOK rats 
at approximately 11 months of age, including the histological evaluation of heart, lung, liver, spleen, kidney, 
and muscle.  H&E-stained sections of heart, lung, liver, spleen, and kidney revealed no apparent differences in 
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the organ histology when comparing wild-type and DGUOK rats.  Liver fibrosis was further evaluated using 
Masson trichrome staining, which also showed no evident differences between wild-type and DGUOK livers. In 
contrast, there were marked differences on oxidative enzyme staining when comparing the quadriceps 
muscles of wild-type and DGUOK rats (Figure 2).  While pathological differences were not apparent on H&E 
staining, there were numerous fibers that showed negative staining on both cytochrome oxidase (COX) and 
succinate dehydrogenase (SDH) stains (Figure 2).  Large numbers (up to 20-30% of fibers) of these COX 
negative/SDH negative fibers were seen in all DGUOK rats, whereas they were essentially absent in all of the 
wild-type rat muscles examined.     
 Expression of respiratory chain complexes. Mitochondrial protein expression was found to be altered in 
quadriceps muscle of the 11 month old DGUOK rat (Figure 3). Specifically, the data indicated that Complex I 
was significantly under-expressed (54 % of wild-type; p = 0.05) and suggested that Complex III was also under 
expressed (47 % of wild-type; p = 0.12). The expression levels of Complexes II, IV & V were unchanged in 
DGUOK rat muscle. Varying, though generally low, amounts of an unidentified immunoreactive protein with Mr 
 30 kDa were also observed.  
 Electron chain transport assays. Significantly lower activities for Complexes I, III and IV were observed 
in DGUOK rat liver, corresponding to about 20 %, 7 % and 13 % of wild-type activity, respectively, whereas 
Complex II activities were statistically indistinguishable (Figure 4, Table 1). In DGUOK muscle, the activities of 
Complexes I and III were only 9 % and 20 % of wild-type, respectively, whereas Complex II and IV activities 
were essentially indistinguishable.     
 EPR spectroscopy. The EPR spectra at 10 K12 K of liver, quadriceps muscle and heart from wild-type 
and DGUOK rats are shown in Figure 5. The signals are complex but some features are immediately 
identifiable and are labeled a - k in Figure 5. Feature a at g' ~ 6 is due to high-spin ferriheme; b at g' ~ 4 is due 
largely to Fe(III) in transferrin; a complex pattern extending upfield from c is due to Mn(II), which is prominent in 
liver but much less so in quadriceps muscle and not detectable in heart, and overlaps the signals from the 
respiratory chain iron sulfur clusters; the prominent feature at d is the so-called "g = 2.01" signal and is due to 
overlapping signals from the oxidized 3Fe4S clusters of Complex II and oxidatively-damaged aconitase; the 
signal at e, the so-called "g = 1.94" signal, is due to overlapping g2 resonances from reduced 2Fe2S and 
4Fe4S clusters, primarily those from Complex I; the signals at f are the g3 resonances from Complex I N4 
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4Fe4S (lower field) and Complex I N3 2Fe2S (higher field) and are overlaid on the highest field mI = 
5/2 
resonance of the mS = 
1/2 manifold of S = 
5/2 Mn(II) (the latter is not clear in trace A but much more pronounced 
in trace B); the resonances labeled g are gx and gy of the rhombic high-spin ferriheme of catalase (88); the 
resonances around h are due to low-spin ferriheme; feature i is the g1 (gx) resonance of low-spin heme a of 
Complex IV; and k indicates the g1 (gx; lower field) and g3 (gz; higher field) resonances from the Rieske 2Fe2S 
cluster of Complex II. The broad EPR absorption in the liver spectra from about 2000 G is largely due to rapid-
passage of the Mn(II) leading to an absorption-like signal that includes components from the mS = 
3/2 and mS = 
5/2 manifolds (127), along with some contribution from CuA of Complex IV. 
 Visual inspection of the spectra provides some limited information. Mn(II) is clearly elevated in DGUOK 
liver whereas the reduced Complex I FeS signals (e, f) are diminished. In DGUOK quadriceps muscle, the 
Complex I FeS signals and the Complex III Rieske signals are markedly diminished compared to wild-type. In 
both muscle and liver, the g = 2.01 signal (d) due to Complex II S3 and/or aconitase appears elevated in 
DGUOK compared to wild-type. To further investigate this phenomenon, spectra were recorded at 40 K 
(Figure 6) where the faster-relaxing S3 signal intensity is lowered relative to the more slowly relaxing 
aconitase signal. In liver, the difference in intensity of the g = 2.01 signal persists and we assign this as being 
due to a 25 % increase in the aconitase signal in DGUOK over wild-type. In quadriceps muscle at 40 K, the 
DGUOK signal is now smaller than the wild-type signal, indicating that the difference at 10 K12 K is due to 
elevated amounts of oxidized Complex III S3 3Fe4S. Clear signals due to g1 (gx) of heme a of Complex IV 
were only observed in heart. The signals in liver and quadriceps were much broader and suggestive of a 
distribution of g-values; this resonance position of this signal was found to be very sensitive to mutations in 
bacterial cytochrome c oxidase (128) and the apparent distribution of g1 values may reflect multiple 
environments in liver mitochondria. In liver, the signal from transferrin was elevated and that from catalase was 
depressed. Interestingly, no significant differences at all were observed between the EPR spectra of heart from 
wild-type and DGUOK rats. 
 For quantitative information we turned to computer simulation of the spectra. Figure 7 shows the g ~ 2 
region of the experimental spectra for liver (A, B), quadriceps muscle (E, F) and heart (I, J) from DGUOK and 
wild-type rats. In each case, fits to the library of computed spectra were generated. As we are particularly 
interested in the differences between wild-type and DGUOK, difference spectra (DGUOK minus wild-type) of 
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the experimental data (C, G and K for liver, muscle and heart, respectively) and the computed fits (D and H for 
liver and muscle; no significant difference was observed between the fits to wild-type and DGUOK heart) are 
presented. The experimental and computed difference spectra match very well and details of the fits are given 
in Table 2/Table S2. From the fit parameters, and using the dual temperature study to resolve the S3 and 
aconitase 3Fe4S contributions, we calculated the fractional difference between the intensities of each of the 
components in the DGUOK and wild-type tissues, and the significant results are summarized in Figure 8. 
 
Discussion. 
 The aims of this work are to describe the DGUOK rat mitochondrial phenotype and evaluate it as a 
model for mitochondrial disease, and to apply EPR spectroscopy of tissue to enable an understanding of what 
happens at the electron level in tissue with mtDNA depletion. The DGUOK rat has a complex and tissue-
dependent mitochondrial phenotype. The DGUOK liver exhibited markedly lower mtDNA copy number, ~ 10 % 
of wild-type. However, EPR showed that Complex I FeS clusters were present at least 50 % as much as in 
wild-type, and signals from S1, S2, S3 and the Rieske FeS clusters indicated that Complexes II and III are 
expressed at the same level as in wild-type. The observation that the four EPR-detectable FeS cluster signals 
are depleted by the same amounts, despite very different redox potentials, and that signal intensities from both 
the S1-S2 pair and the Rieske cluster are indistinguishable from wild-type suggests that (i) the lowered 
Complex I signals are due to depressed expression or Fe incorporation, rather than an elevated redox potential, 
and (ii) the depleted Complex I complement therefore provides sufficient electrons to load the electron transfer 
chain. The aconitase 3Fe4S signal, a characteristic marker for oxidative stress (82), was elevated in DGUOK 
liver. Also, Mn(II), which is present at high levels in wild-type liver and is proposed to be additionally generated 
in response to oxidative stress (127), was doubled compared to wild-type. The activities of Complexes I, III and 
IV in DGUOK liver were very depressed compared to wild-type, and by far more that can be accounted for by 
expression levels. It is tempting to speculate that the oxidative stress identified by the aconitase and Mn(II) 
EPR signals is either a cause or consequence of the additional Complex I, II and IV dysfunction in DGUOK 
liver. The very low levels of Complexes III and IV activities explain the EPR observation that the electron 
transfer chain remains electron-rich, and the redox potential maintained close to the NADH:NAD midpoint 
potential, even though Complex I activity is also significantly depressed. The elevation of the EPR signal from 
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transferrin may indicate some hemorrhaging, and the depression of the catalase signal also suggests some 
disease or damage to the liver (129). 
 The mitochondrial phenotype in DGUOK quadriceps muscle is also complex. Consistent with muscle 
evaluated in humans with severe disease, protein expression levels for Complexes I and III were also ~ 50 % 
of wild-type, whereas Complexes II, IV and V were expressed at wild-type (108). However, in contrast to 
humans with severe disease, the mtDNA copy numbers for wild-type and M2 DGUOK were similar across all 
muscle groups [table S1]. This lack of difference in the muscle types may reflect variability in sampling, the 
milder phenotype in the rats or an underlying correction in muscle tissue for example by de novo purine 
synthesis or alternate salvage pathways. This data underscores the limited sensitivity of qPCR previously 
described in human muscle (112) and emphasizes the need to consider evaluation of liver specifically for 
depletion in this disease. 
Consistent with protein expression levels, EPR of DGUOK quadriceps muscle indicated that Complex I 
is present at  35 % of the wild-type level and Complex III at about 50 %. The EPR data for Complex II are 
revealing. The S3 cluster signal was twice as intense as in wild-type, yet the S1 and S2 clusters were 
diminished by a factor of two. This could indicate a catastrophic inability to correctly assemble Complex II or 
incorporate S1 and S2 but this would be expected to essentially abolish activity, and the elevation of S3 would 
require a doubling of Complex II expression. Neither phenomenon was observed. More likely, the changes in 
S1, S2 and S3 reflect a Complex II that experiences a significantly more oxidizing redox potential than in wild-
type mitochondria. This hypothesis is strongly supported by the very low Complex I electron transferring 
activity compared to the downstream activities of Complexes II, III and IV. Therefore, Complex II is drained of 
electrons and produces the EPR signature observed in DGUOK quadriceps muscle. This scenario also 
explains the lack of markers for oxidative stress in the EPR signature of DGUOK muscle. In the absence of 
Complex I activity, very few electrons enter the respiratory chain to begin with. Furthermore, the downstream 
components are in a more oxidized state and thus are primed to receive any electrons that do enter the 
respiratory chain, essentially acting as antioxidants. So, while Complex III dysfunction results in electron build-
up and oxidative stress in DGUOK liver, the lack of activity of Complex I and downstream oxidation of 
Complexes II - IV in muscle does not result in oxidative stress even though Complex III activity is as depressed 
in muscle as it is in liver. The only EPR marker observed for Complex IV in this study, the heme a signal, was 
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very weak and broad in muscle and was not significant in the fits. Nevertheless, visual examination suggests a 
comparable signal in wild-type and DGUOK, consistent with the significant Complex IV activity. What remains 
unclear is the reason(s) behind the low activities of Complexes I and III. Native PAGE provides no evidence for 
subunit depletion, and EPR does not indicate oxidative stress. 
 In contrast to liver and quadriceps muscle, the heart in the DGUOK rat appears entirely unaffected. The 
mtDNA copy numbers are normal and the EPR signals of wild-type and DGUOK heart are indistinguishable 
themselves and very similar to wild-type quadriceps muscle. Large EPR signals from Complex I N3 and N4, a 
large signal from Complex III Rieske 2Fe2S, a high ratio of the g = 1.94 and g = 2.01 signals, and a weak 
signal from Complex IV heme a all indicate a very reducing environment that is consistent with an active 
Complex I and a fully functioning respiratory chain that does not produce oxidative stress. 
 EPR is a unique tool in that it can interrogate the status of the mitochondrion at the time of freezing, in 
unprocessed viable biological samples. First, it is clear that in both liver and quadriceps muscle, EPR identified 
mitochondrial dysfunction in the DGUOK rat. Second, some mechanistic information on the DGUOK rat was 
obtained. In liver, the EPR results indicated that the reduced electron transfer chain activity of Complexes I is 
in part due to reduced expression but that the very low activity of Complex, III is not a consequence of reduced 
expression or Fe incorporation as FeS clusters. The retention of the Complex III Rieske 2Fe2S EPR signal in 
DGUOK liver indicates that Complex III is present at wild-type levels, incorporates the Rieske cluster, and 
electrons can progress through the respiratory chain at least as far as the Rieske cluster. The reason for 
Complex III inactivity remains unknown but appears to be downstream of the Rieske cluster. Oxidative stress 
may be important, and two independent markers for oxidative stress were identified, elevated aconitase 3Fe4S 
and Mn(II); two markers for liver damage were also identified, depressed catalase and elevated transferrin. In 
quadriceps muscle, EPR provides complementary information to the activity assays. The lack of Complex I 
activity and the EPR identification of oxidation of the three Complex II FeS clusters provides a rationale for the 
lack of any EPR markers for oxidative stress in muscle. A knowledge of whether oxidative stress is a 
consequence of mitochondrial disease, and in which tissues and why, is an important piece of information that 
may inform therapy choices.  
 
Conclusions. 
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The DGUOK rat capitulates major biochemical features observed in humans with DGUOK deficiency, 
specifically significantly reduced mtDNA content, reduced mitochondrial complex I, III and IV protein content 
and enzymatic activity in frozen liver.  EPR assessment of flash-frozen tissues has demonstrated dramatic 
differences in the mitochondrial electron transport chain status in situ compared with wild-type animals. The 
reproducibility and magnitude of these differences is encouraging given the relatively mild pathologic 
differences seen in the animals. It suggests that EPR may be able to reliably distinguish individuals with 
mitochondrial disease from distinct etiologies of muscle or liver disease in humans.   
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1000 x Wild-type 
activity  citrate 
synthase activity 
 
1000 x DGUOK 
activity  citrate 
synthase activity 
Mann-Whitney 




LIVER     
Complex I 230.08 ± 18.81 47.64 ± 9.53 0.008 0.002 
Complex II 991.9 ± 95.3  1291.6 ± 258.3 0.522 0.250 
Complex III 14.35 ± 0.80 1.02 ± 0.20 0.008 0.001 
Complex II - III 430.1 ± 32.6 129.3 ± 25.9 0.029 0.012 
Complex IV 137.54 ± 11.69 17.70 ± 3.54 0.014 0.002 
     
MUSCLE     
Complex I 108.1 ± 8.25 9.73 ± 4.25 0.008 0.015 
Complex II 278.1 ± 16.42 215.8 ± 18.41 0.522 0.093 
Complex III 3.43 ± 0.48 0.70 ± 0.18 0.036 0.025 
Complex II -III 263.7 ± 28.53 157.6 ± 15.36 1.00 0.070 
Complex IV 38.63 ± 5.60 53.93 ± 8.76 0.412 0.434 
 
Table 1. Results of electron transport chain assays of Complexes I - IV from muscle and liver from wild-type and 
DGUOK rats. 
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CuA 47 ± 13 44 ± 15 
[NS]c 
9 ± 1 13 ± 1 
[+45] 
NDd 
Heme a 200 ± 50 100 ± 60 
[-50] 
ND ND 200 ± 30 
High-spin heme 116 ± 7 71 ± 9 
[-39] 
44 ± 1 31 ± 1 
[-30] 
183  3 
N1b + N2 26 ± 5 16 ± 5 
[-39] 
28.2 ± 0.2 7.4 ± 0.5 
[-74] 
111  1 
FeS N3 17 ± 8 8 ± 5 
[-53] 
16 ± 1 5.5 ± 0.7 
[-61] 
38  4 
FeS N4 41 ± 8 20 ± 6 
[-51] 
33 ± 1 14 ± 1 
[-59] 
108  4 
All Complex I FeS 84 ± 12 44 ± 9 
[-49] 
77 ± 1 26 ± 1 
[-66] 
257  6 
S3 + Acn 10.8 ± 1.6 15 ± 2 
[+37] 
1.3 ± 0.1 3.8 ± 0.1 
[+192] 
17  1 
FeS S1 27 ± 10 29 ± 13 
[NS] 
15 ± 1 8 ± 1 16 ± 5 
FeS S2 ND ND ND ND 60 ± 5 
S1 + S2 27 ± 10 29 ± 13 
[NS] 
15 ± 1 8 ± 1 
[-48] 
76 ± 7 
Rieske FeS 99 ± 11 98 ± 12 
[NS] 
37 ± 1 18 ± 1 
[-51] 
238 ± 5 
Mn(II) 295 ± 27 588 ± 32 
[+99] 




Table 2. Fitting parameters for the EPR signals from spectra of liver and muscle tissue from wild-type and DGUOK rats. 
The absolute intensities of each species (or group of species) are shown for wild-type and DGUOK, along with the 
percentage differences between DGUOK and wild-type intensities in brackets. 
 
Footnotes. (a) Calculated as {[(DGUOK signal) - (wild-type signal)]  (wild-type signal)}  100. (b) Wild-type and 
































Figure 1. Absolute mtDNA content in DGUOK rats. The mtDNA copy numbers for eight week old M1 and M2 
DGUOK knockout rats compared with wild-type (SS) rats. The error bars indicate standard deviations for n = 6 (SS), n = 
4 (M1) and n = 3 (M2). 
 








Figure 2: Skeletal muscle pathology in 11 month old WT and DGUOK rats.  Quadriceps muscles from DGUOK rats 
display little differences on H&E staining in comparison to WT littermates.  In contrast, staining for COX and SDH 
reveals numerous fibers in DGUOK rat muscle that are negative for both COX and SDH, whereas no such fibers were 
evident in WT rat muscle.  The bar at the bottom, right corresponds to 200 m. 
  






































Figure 32. Respiratory chain complex expression in DGUOK rat muscle. Western blots of mitochondrial electron 
transport chain complexes I-V and GAPDH from stripped membranes of quadriceps muscle from 11 month old wild-type 
and DGUOK rats are shown in the top panel. The results of quantitation of the respiratory chain complex bands are shown 
below, normalized for GAPDH expression. The error bars indicate standard deviations errors for n = 4.  
  







































 Figure 43. Electron transport chain functional assays of Complexes I - IV. The functional activities of 
Complexes I - IV from liver and quadriceps muscle of DGUOK rat are shown, normalized for mitochondrial content (as 
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Figure 5. 12 K EPR spectra from wild-type and DGUOK rat tissue. The spectra are from samples of A, wild-type rat 
liver; B, DGUOK rat liver; C, wild-type rat quadriceps muscle; D, DGUOK rat quadriceps muscle; E, wild-type rat heart; 
and F, DGUOK rat heart. In each case, the sample completely filled the part of the EPR tube that occupied the active 
region of the resonator. A & B shown x 1, C & D are shown x 2, and E & F shown x 0.5. Spectra were recorded at 12 K, 
2.5 mW power. The lower-case labels identify specific signals in the spectra: (a) high-spin axial ferriheme g; (b) 
transferrin non-heme Fe(III); (c) the mI = 
5
/2 line at the low-field extremity of the six-line Mn(II) hyperfine pattern; (d) 
overlapping signals from aconitase and S3 [3Fe4S] clusters; (e) overlapping g2 resonances from Complex I [2Fe2S] and 
[4Fe4S] clusters; (f) resolved g3 resonances from N4 and N3 clusters; (g) high-spin catalase gx and gy lines; (h) low-spin 
catalase resonances; (i) heme a g1; and (k) Rieske [2Fe2S] cluster g1 and g3 resonances. 
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Figure 6. 40 K EPR spectra from wild-type and DGUOK rat tissue. The spectra are from samples of A, wild-type rat 
liver (solid line) and DGUOK rat liver (dashed line); and B, wild-type rat quadriceps muscle (solid line) and DGUOK rat 
muscle (dashed line). Spectra were recorded at 40 K, 2.5 mW power.  
 
  








































Figure 7. Quantitative analysis of the 12 K EPR signals from wild-type and DGUOK rat tissues. Traces A, B, E, F, I 
and J show the g' ~ 2 region of the EPR spectra of A, wild-type rat liver; B, DGUOK rat liver; E, wild-type rat 
quadricepquadriceps muscle; F, DGUOK rat quadricepquadriceps muscle; I, wild-type rat heart; and J, DGUOK rat heart. 
Trace C is the difference spectrum obtained by subtraction of A from B, and is shown multiplied by a factor of two; 
likewise, G = 2(F - E) and K = 2(J - I). Trace D is a theoretical simulation of C generated by the subtraction of fits of A 
and B to model spectra of the paramagnetic species likely to be observed in the mitochondrion. Fitting parameters are 
presented in Table 2 (or S2). Similarly, trace H is a simulation of J from fits to E and F. No attempt was made to simulate 
K, as no significant differences were observed between fits to I and J. 
 
  


































Figure 8. Summary of EPR of DGUOK rat liver and muscle. A comparison of signal intensities is shown for some of 
the respiratory complex redox centers in liver and muscle from the DGUOK and wild-type rat. The standard errors were 
calculated from those of the fit parameters, presented in Table 2 (or S2). 
 
  




In contrast to liver (n=5), mtDNA content in muscle tissue from 4 Wild Type (Dahl/SS) rats compared with 4 
DGUOK M2 rats demonstrates no significant difference. 
  
 WILD TYPE RAT DGUOK M2 RAT TTEST 
SOLEUS MUSCLE 1036 710 0.72 
GASTROCNEMIUS MUSCLE 910 571 0.31 
TRICEP MUSCLE 1270 418 0.25 
DELTOID MUSCLE 1043 1043 0.81 
LIVER 1981 187 0.0002 
 
